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Translational blockageAntisense oligonucleotides are synthetic single stranded strings of nucleic acids that bind to RNA and thereby
alter or reduce expression of the target RNA. They can not only reduce expression of mutant proteins by break-
down of the targeted transcript, but also restore protein expression ormodify proteins through interferencewith
pre-mRNA splicing. There has been a recent revival of interest in the use of antisense oligonucleotides to treat
several neurodegenerative disorders using different approaches to prevent disease onset or halt disease progres-
sion and the ﬁrst clinical trials for spinal muscular atrophy and amyotrophic lateral sclerosis showing promising
results. For these trials, intrathecal delivery is being used but direct infusion into the brain ventricles and several
methods of passing the blood brain barrier after peripheral administration are also under investigation.
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Fig. 1. Routes for delivery of antisense oligonucleotides to the central nervous system.
Next to systemic delivery, antisense oligonucleotides can be directly delivered into the
cerebrospinal ﬂuid through intracerebroventricular or intrathecal infusion using an
implanted reservoir that is connected to the ventricles within the brain or spinal cord
via an outlet catheter. Analternative less invasive route of delivery of antisense oligonucle-
otides could be conceivable via intranasal administration.
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There has been a recent revival of interest in the use of antisense
oligonucleotides to treat neurodegenerative disorders. Antisense
oligonucleotides are synthetic single stranded strings of nucleic acids,
between 8 and 50 nucleotides in length, that bind to RNA through
standard Watson–Crick base pairing. Antisense oligonucleotides
interfere with gene expression by altering RNA function. Depending
on sequence and modiﬁcations, antisense oligonucleotides can alter
RNA function through several distinct mechanisms, making them a
diverse tool. They can be used to restore protein expression, reduce
expression of a toxic protein, or modify mutant proteins to reduce
their toxicity. Antisense-mediated gene inhibition was ﬁrst introduced
by Stephenson and Zamecnik in 1978 [1]. Using a DNA molecule of 13
nucleotides in length with modiﬁcations at the 3′ and 5′ OH moieties,
they showed inhibition of replication and cell transformation of the
Rous sarcoma virus. Since then, modiﬁcations to the backbone and
sugar component have improved stability, binding strength and
speciﬁcity which has made antisense oligonucleotides suitable for
therapeutic application [2]. For several neurodegenerative disorders,
antisense oligonucleotide therapy has now moved from the preclinical
to the clinical stage, facilitated by the remarkable widespread
distribution and cellular uptake of antisense oligonucleotides once
delivered into the brain [3,4].
There are many other types of nucleic acid molecules that can
interfere at the RNA level using the RNA-induced silencing complex
(reviewed in [5]) that promote selective degradation of homologous
cellular mRNAs, but these will not be discussed. In this review we will
outline the key characteristics of antisense oligonucleotides that make
them very suitable for treating neurological disorders. We will discuss
the delivery of antisense oligonucleotides to the nervous system and
the available chemical modiﬁcations of antisense oligonucleotides that
have been applied to neurodegenerative disorders. Finally different
functional mechanisms to alter RNA function in the nervous system
will be discussed, as well as several neurodegenerative disorders
where these different antisense oligonucleotide mechanisms are being
applied.
2. Delivery to the nervous system
In drug discovery, the aim is to ﬁnd a substance which is potent,
selective, and preferably bioavailable that needs to reach its target at
sufﬁcient concentrations [6]. For drugs to reach the nervous system
they ﬁrst have to cross the vascular barrier, which is made up of the
blood brain barrier (BBB) or the blood–spinal cord barrier (BSCB).
These vascular barriers prevent most molecules from entering the
nervous system from the blood circulation. Despite this gate-controlling
system, essential nutrients, such as glucose, are permitted to pass [7].
The vascular barriers of the nervous system are comprised of amonolayer
of endothelial cells forming tight junctions through interactions of cell
adhesion molecules [8]. Other structural components are astrocytes that
surround the endothelial cells with their processes, pericytes located
between the endothelial cells and astrocytes, macrophages, and ﬁnally
the basement membrane. The endothelial cells of the BBB are
characterised by only few fenestrae and pinocytic vesicles, limiting
transport to and from the brain. The BBB thus also largely separates
the peripheral immune system from the brain. Although the BSCB is
largely made up of the same components as the BBB, there are some
functional and morphological differences [9]. For instance in the BSCB,
the equivalent of the BBB endothelial cells is the choroid plexus
epithelial cells [10] and the permeability of the two barriers is different
probably due to differences in tight junction protein expression [11]. In
neurodegenerative diseases, disruption of the vascular barrier is com-
mon [8,12,13] and it was shown in animal models that a compromised
BBB barrier in itself can lead to neurodegeneration [12]. However,
for most diseases of the nervous system that could be treated withantisense oligonucleotides, the antisense oligonucleotides will not be
able to cross the vascular barrier when delivered systemically. Several
methods have been used to deliver antisense oligonucleotides to the
nervous system (see Fig. 1). Antisense oligonucleotide modiﬁcations
will largely determine the most efﬁcient route of delivery. In this
chapter the different mechanisms for antisense oligonucleotides to
enter the nervous system will be outlined. We will next review the
different types of antisense oligonucleotide modiﬁcations used for
neurodegenerative disorders in chapter 3.
2.1. Peripheral delivery
Efforts are ongoing to deliver antisense oligonucleotides to
the nervous system via the systemic route. In general, when a drug is
administered systemically, a fraction will be bound to proteins
(e.g. serum albumin, lipoprotein etc.) and a fraction will be unbound.
The bound fraction is the pharmacologically relevant fraction, since it
is available to cross the vascular barrier [8] depending on its physico-
chemical properties.
The ﬁrst mechanism by which antisense oligonucleotides could
cross the vascular barrier is simple diffusion. Small lipophilic substances
which have a hydrogen bond aremore likely to pass the vascular barrier
[14] than compoundswithout hydrogen bonds and onlymoleculeswith
a molecular weight smaller than 400 Da are able to cross the vascular
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weight of approximately 6000 to 10,000 Da and thus are too large to
cross the vascular barrier by simple diffusion and reach an effective
concentration in the nervous system. Indeed, early studies showed that
only limited brain uptake of peripherally administered radioactive anti-
sense oligonucleotides with less than 1% of the injected oligonucleotide
is measured in brain [16–19]. The mechanism by which this antisense
oligonucleotide crossed the BBBwas named the saturable oligonucleotide
transport system [17].
Another mechanism to cross the vascular barrier is via receptor-
mediated endocytosis, which allows macromolecules, such as transfer-
rin, insulin, leptin, and insulin-like growth factor 1, to enter the nervous
system [20]. Studies by Lee and associates used biotinylated antisense
oligonucleotides captured with a streptavidin conjugated radioactive
labelled monoclonal antibody to the mouse transferrin receptor to
quantify gene expression in vivo [21]. This radioactive labelled antisense
oligonucleotide conjugate reached the brain through the endogenous
transferrin transport pathway (receptor-mediated endocytosis) in a
transgenic mouse model [21]. This same transferrin transport pathway
was used to transport nanoparticles carrying antisense oligonucleotides
targeting aquaporin 4 into the brain parenchyma [22].
More recent research has focussed on cell-penetrating peptide
(CPP)-based delivery systems [23]. These have shown strong
transmembrane capacity and great potential for therapeutic approaches
for neurodegenerative disorders [24]. CPPs can be up to 30 amino acids
in length and can carry a wide variety of cargos. Different CPPs use
distinct cellular translocation pathways, which depend on cell types
and cargos [25]. Systemically delivered antisense oligonucleotides
tagged with arginine-rich CPPs were able to cross the BBB and were
widely distributed throughout the brain of wild-type mice [26]. To
note, not all types of antisense oligonucleotide modiﬁcations are
suitable for coupling with CPPs. Although two promising CPP antisense
oligonucleotides were abandoned as therapeutic agents since repetitive
intravenous (IV) bolus injections of CPP antisense oligonucleotides
caused lethargy and weight loss in rats [27] and tubular degeneration
in the kidneys of monkeys [28], CPP systems are still a promising
delivery system.
Although not tested thus far, antisense oligonucleotides encapsulated
in exosomeswould theoretically also be able to cross the vascular barrier
after IV injection. Exosomes are a well-studied class of extracellular ves-
icles known to mediate communication between cells through transfer
of proteins andnucleic acids [29,30]. IV injection of exosomes transduced
with short viral peptides derived from rabies virus glycoprotein (RVG)
resulted in crossing of the BBB and siRNA delivery to the brain [31].
These IV injected RVG-targeted exosomes bound to neurons, microglia
and oligodendrocytes, resulting in a speciﬁc gene knockdown in the
brain [29].
2.2. Direct delivery to the nervous system
Besides mechanisms to cross the vascular barriers, there are also
techniques that bypass them through direct infusion into the cerebro-
spinal ﬂuid (CSF).
Antisense oligonucleotides can be infused intracerebroventricularly
(ICV) after which the ASOs would have to pass the ependymal cell
layer that lines the ventricular system to enter the parenchyma. Intra-
thecal (IT) delivery means delivery of the ASOs into the subarachnoid
space of the spinal cord. From here it will have to pass the pia mater
to enter the parenchyma. ASOs can be delivered ICT or IT through an
outlet catheter that is connected to an implanted reservoir. Drugs can
be injected into the reservoir and delivered directly to the CSF.
This route of delivery has several advantages over peripheral adminis-
tration. It results in immediate high drug concentrations in the CSFmean-
ing that a smaller dose can be used, potentially minimizing toxicity. Also,
because there is free exchange between the CSF and brain parenchyma,
and the BBB prevents transport of the antisense oligonucleotides intothe peripheral circulation, direct delivery into the nervous system can rel-
atively rapidly result in therapeutic drug concentrations. This infusion
technique was used in antisense oligonucleotide applications in rodent
models of neurodegenerative disorders as well as non-human primates
[32].Moreover, IT drug therapy has been applied to awide variety of neu-
rological conditions [33,34]. To date there have been two phase I clinical
trials completed using IT infusion of antisense oligonucleotides in
amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA)
patients [35,36] without any major adverse side effects [35].
2.3. Intranasal delivery to the brain
Although to date there have been very few studies showing delivery
of antisense oligonucleotides to the brain via intranasal administration,
this is a very promising alternative route of delivery. After intranasal
administration, molecules can be transported along the olfactory and
trigeminal nerve pathway and the rostral migratory stream [37]. It is
less invasive compared to the above mentioned antisense oligonucleo-
tide deliverymethods and alreadywas used successfully in clinical trials
showing improved cognition after intranasal insulin application in
Alzheimer disease patients [38]. Also intranasal delivery of small
interfering RNA (siRNA)was shown to be very efﬁcient. CPP conjugated
to glycol–polycaprolactone copolymers was able to target siRNAs to the
brain via the intranasal route [39]. In rats, intranasal delivery of
antisense oligonucleotides was found to lead to good distribution
throughout the brain, and was able to slow down intracerebral tumour
growth [40]. These studies hence indicate that intranasal delivery may
become a viable option for antisense oligonucleotide delivery in the
future.
3. Chemical modiﬁcations
Initially, antisense oligonucleotides were used in the form of
synthetic unmodiﬁed DNA [41]. Though successful, these types of
oligonucleotides proved very susceptible to degradation by endo- and
exonucleases. It quickly became apparent that if antisense oligonucleo-
tides were to be used for clinical applications, their pharmacological
proﬁle would have to be enhanced. Oligonucleotides have since beneﬁt-
ed from technical advances in chemical modiﬁcations leading to
signiﬁcantly improved characteristics. Antisense oligonucleotides are
available with a range of different modiﬁcations on the phosphate
backbone and ribose sugar group in the case of RNA (see Table 1). The
modiﬁcations used in studies of neurodegenerative disorders and their
mode of actions will be discussed in the paragraphs below.
3.1. Backbone modiﬁcations: counteracting nucleases
One of the main factors impeding antisense oligonucleotide efﬁcacy
is their rapid degradation by endo- and exonucleases. A 3′ to 5′ exonu-
clease is able to degrade unprotected antisense oligonucleotides within
30 min in serum [42], whilst intracellular exo- and endonucleases can
lead to degradation in an even shorter timespan [43]. Brain associated
α-exonuclease is likely responsible for degradation of antisense
oligonucleotides in CSF [4]. One of theﬁrst successfulmodiﬁcations pro-
viding a good degree of protection from these nucleases is the phospho-
rothioate (PS) backbone. Termed the ﬁrst generation of oligonucleotide
modiﬁcations, the PS backbone is accomplished by replacement of one
of the non-bridging oxygen atoms in the backbone with a sulphur
atom [44]. Oligonucleotides with this modiﬁcation are more stable
with reported half-lives of 9 h in human serum and 19 h in rat CSF
[45]. The negative charge of PS DNA furthermore allows for good uptake
into various cell types in vitro [46] and into various brain cell types after
microinjection into brain [47]. Another important characteristic of the
PS backbone is its ability to activate ribonuclease H (RNase H), allowing
for use in applicationswhere target RNAdownregulation is desired [48].
RNase H recognizes an RNA–DNA heteroduplex, and then cleaves the
Table 1
Chemical modiﬁcations of antisense oligonucleotides.
Modiﬁcation Main features Main disadvantages Application Frequency
of use
Refs.
Phosphate
linkage
phosphodiester - Naturally occurring
- Inexpensive
- Rapidly degraded by nucleases
- Quickly cleared by kidney
Steric hindrance
RNase H cleavage
− [47,179–181]
phosphoramidate - High afﬁnity
- High nuclease resistance
- Does not support RNase H
- Quickly cleared by kidney Steric hindrance + [40]
phosphorothioate
(PS)
- Improved nuclease resistance
- Improved binding to plasma proteins
(preventing kidney clearance)
- Can cause immune response/cytotoxicity
at high concentrations
- Slightly reduced binding afﬁnity
compared to phosphodiester
Steric hindrance
RNase H cleavage
+++++ [182–184]
Sugar
modiﬁcation
LNA - Strong binding afﬁnity
- Increased nuclease resistance
- Does not support RNase H
- Higher toxicity than other modiﬁcations
- Higher risk of a-speciﬁc binding
- Higher propensity for self-annealing
Steric hindrance + ++ [78,112,185]
2OMe - Improved binding afﬁnity
- Improved nuclease resistance
- Inhibits immune stimulation of PS backbone
- Does not support RNase H
- Lower afﬁnity than most other
modiﬁcations
Steric hindrance ++++ [186,187]
MOE - Improved binding afﬁnity
- Improved nuclease resistance
- Inhibits immune stimulation of PS backbone
- Does not support RNase H
- Lower afﬁnity than most other
modiﬁcations
Steric hindrance ++++ [32,35,162]
2′-Fluoro - Improved binding afﬁnity
- Does not support RNase H cleavage
- Little improvement for nuclease resistance Steric hindrance + [188]
cEt - Strong binding afﬁnity
- Improved nuclease resistance
- Does not support RNase H
Steric hindrance + + [87,132]
tc-DNA - Improved nuclease resistance
- Improved binding afﬁnity
- Does not support RNase H
- Little research data available Steric hindrance + [82–84]
Non-ribose
modiﬁcations
PMO - Neutral charge
- Improved binding afﬁnity
- Excellent nuclease resistance
- Does not support RNase H
- Rapid clearance
- Poor uptake in cell nucleus
- Poor pharmacokinetic properties
Steric hindrance + ++ [102,113,168,189]
PNA - Uncharged
- High binding afﬁnity
- Low toxicity
- High nuclease resistance
- Rapid clearance
- Poor uptake/pharmacokinetic properties
Steric hindrance + + [96,112,190,191]
Sugar modiﬁcations are typically used together with the PS backbone modiﬁcation. 2OMe: 2′-O-methyl, cEt: S-constrained-ethyl, LNA: Locked nucleic acid, MOE: 2′-O-methoxy-ethyl,
PMO: phosphorodiamidate morpholino oligomer, PNA: peptide nucleic acid, Tc-DNA: tricyclo-DNA.
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intact DNA strand [49,50]. A less favourable characteristic of the PS
backbone is that it destabilize duplexes, leading to a decrease inmelting
temperature [51]. Cytotoxic effects of PS at high concentrations have
been reported (reviewed in [52]), and are thought to be related to
protein binding [53,54] or complement activation [55]. PS modiﬁed an-
tisense oligonucleotides have undergone extensive pharmacokinetic
testing aimed at peripheral administration. In this context, it was
found that PS oligonucleotides bind serum proteins, leading to reduced
renal clearance and an increased circulation time [56,57]. These
favourable pharmacokinetic properties in the periphery are contrasted
by the poor ability of PS oligonucleotides to cross the BBB [58].
3.2. Sugar group modiﬁcations: improving afﬁnity and reducing toxicity
In addition to the PS backbone, RNA oligonucleotides can be further
modiﬁed at the 2′ position of the ribose sugar. These types of modiﬁca-
tions are termed the second generation oligonucleotide modiﬁcation,
and, in combination with the PS backbone, have been of great
importance for advancing oligonucleotide safety and pharmacologic
properties. In this class of modiﬁcations, the 2′-O-methyl (2OMe) and
2′-O-methoxy-ethyl (MOE) have proven most successful thus far.
These modiﬁcations increase hybridization afﬁnity to their target RNA
compared to unmodiﬁed phosphorothioates [59–61], as well as in-
creased resistance towards nuclease degradation [61,62]. An additional
key advantage of the 2′modiﬁcations is their ability to reduce sequence
independent toxicity arising from the PS backbone [63], which also
holds true in the CNS [64]. An important trait of 2′-modiﬁcations is
their inability to recruit RNase H [65] and oligonucleotides that arefully modiﬁed in this fashion thus cannot induce RNase H-mediated
target RNA downregulation.
For 2′-O-modiﬁed-PS antisense oligonucleotides only very mild
toxicity has been reported, which did not interfere with their desired
effects after ICV delivery in rodent brain [66], or in cultured neuronal
cells [67]. Although it has been shown that PS antisense oligonucleo-
tides can have an immunostimulatory effect via toll-like receptors,
appropriate 2′-O modiﬁcations, such as 2OMe and MOE, can suppress
these effects [68–70]. It is important to mention that possible toxic
and immunostimulatory effects of 2OMe-PS antisense oligonucleotides
may also be due to dosage, concentration, or duration of treatment [71].
Locked nucleic acids (LNA) are a 2′-modiﬁcation where the 4′-
carbon has been tethered to the 2′-hydroxyl group. LNAs provide
resistance to nucleases [72] and show much improved hybridization
compared to the other 2′-modiﬁcations [73,74]. LNAs are also unable
to induce RNase H-mediated target RNA downregulation [75,76].
Though LNAs provide a better RNA binding afﬁnity than most other
2′-modiﬁcations, there appear to bemore severe toxicological problems
with these oligonucleotides in systemic treatment [77]. Whether this
also holds true for the CNS will remain to be determined, though one
study reports that LNAs are tolerated in rat brain [78]. Additionally,
the high afﬁnity of LNAs can lead to a reduction in target speciﬁcity
[74,79]. For these reasons, a chimera design where LNAmodiﬁed nucle-
osides are interspersed by unmodiﬁed or differently 2′O-modiﬁed
nucleosides can be implemented [73]. LNAs can be further modiﬁed
by addition of oligospermine nucleobases. The resulting antisense
oligonculeotide–oligospermine conjugates are known as zip nucleic
acids (ZNA) [80]. These conjugates lack the polyanionic nature and elec-
trostatic repulsion of the negatively charged phosphate backbones,
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ZNA conjugates were found to reduce huntingtin expression in
Huntington disease (HD) patient-derived cells [81]. Although ZNA
conjugates are primarily used as probes for real-time PCR, they possess
some therapeutically interesting properties.
Another conformationally constrained oligonucleotide modiﬁcation
available is tricyclo-DNA (tc-DNA). This modiﬁcation is aimed at lessen-
ing the ﬂexibility around the C3′–C4′ and C4′–C5′ bonds by addition of
an ethylene bridge fused with a cyclopropane unit. The result in a
more stable duplex formation [82] that is not compatible with RNase
H. Tc-DNA has been reported to be stable in serum and resulted in
more potent splicing correction compared to a 2OMe-PS oligonucleo-
tide when tested in cells [83]. To date, there have been very few studies
performedmaking use of tc-DNA, but there has been one report stating
splicing modulation in the brain occurred after peripheral administra-
tion of tc-DNA in a Duchenne muscular dystrophy mouse model [84].
Interestingly, dystrophin restoration in the mouse brain resulted in
complete reversal of its behavioural phenotype [84].
Other sugarmodiﬁcations less frequently used in CNS studies are the
2′-ﬂuoro and S-constrained-ethyl (cEt) oligonucleotides. The 2′-ﬂuoro,
akin to OMe and MOE modiﬁcations, replaces the 2′-hydroxy with a
ﬂuoro group and provides a higher afﬁnity thanmost other 2′-modiﬁca-
tions [65], in addition to providing resistance to nucleases [85]. The cEt
modiﬁed antisense oligonucleotides provide similar binding afﬁnity as
LNA, yet appear to have a more favourable toxicity proﬁle [86], and
have recently shown good promise in a humanized mouse model for
HD [87].
Taken together, the second generation of oligonucleotide modiﬁca-
tions has provided a good degree of improvement on the PS backbone,
with enhancements in nuclease resistance, binding afﬁnity and reduc-
tion of PS-induced toxicity. However, in light of the fact that most CNS
research utilising oligonucleotides aims at downregulation of target
RNA, the fact that these modiﬁcations are not compatible with RNAse
H cleavage is an important consideration. For this reason, a RNAse H
compatible gapmer strategy was conceived of (described in Section 4),
in which a PS oligonucleotide is not modiﬁed with 2′O-modiﬁcations
over its entire length. Importantly, a MOE-PS gapmer oligonucleotide
was the ﬁrst to make it to clinical trials for a neurodegenerative
disorder, and has shown favourable tolerability [35].
3.3. Other oligonucleotide modiﬁcations
Besides the PS backbone and several ribose sugar modiﬁcations
described above, efforts have been made with newer modiﬁcations
that combine backbone, ribose and nucleosides modiﬁcations.
Peptide nucleic acids (PNA) are generated by replacement of the
entire sugar phosphate backbone with polyamide linkages [88], but
are still able to hybridize through Watson–Crick binding [89]. PNAs
are uncharged, and provide a high resistance to nuclease and protease
degradation [90]. Another important feature of PNAs is their high bind-
ing afﬁnity for RNA [91]. In light of their inability to activate RNAse H,
PNAs are mostly implemented in splicing modulation approaches or
translation inhibition. A clear shortcoming of PNAs is their poor cellular
uptake [92] and water insolubility [93]. However, both uptake and
water solubility can be improved using peptide conjugates [94,95].
Uptake in neuronal cells of unmodiﬁed PNA in vivo has been reported
[96] but the use of PNA antisense oligonucleotides in neurodegenerative
disorders remains somewhat limited. When administered peripherally,
PNAs are rapidly cleared [97] and these poor pharmacokinetic proper-
ties likely in part explain their limited in vivo use thus far.
Phosphorodiamidate morpholino oligomers (PMO) have a
morpholine ring instead of the ribose ring, and have phosphoroamidate
intersubunit linkages. Similar to PNAs, PMO backbones are neutrally
charged and are not compatible with RNase H [98]. PMOs are highly re-
sistant to nuclease and protease degradation [99]. In a phase 1 clinical
trial using IV administration, PMOs were well tolerated, but wereshown to suffer from the same pharmacokinetic shortcomings as
PNAs since they are rapidly cleared from the blood [100]. Peptides can
be conjugated to the PMO for improved cellular uptake and pharmaco-
kinetics [101]. Also, bare PMO chemistry has been successfully used to
modify splicing when administered directly in mouse brain [102],
though toxicity at higher doses may occur [103]. Another interesting
conjugated PMO is the vivo-morpholino, which features a terminal
octaguanidinium dendrimer aimed at improving cell permeability and
thus tissue uptake when administered peripherally [104]. Unfortunate-
ly, there have been reports of severe toxicity following IV administration
of vivo-morpholino in mice [105]. Importantly, the increased toxicity of
vivo-morpholino compared to bare PMOs also appears to hold true in
the brain [103,106]. Crossing of the BBB does not appear to occur
efﬁciently for vivo-morpholinos [107], and, though microinjection in
rat brain was effective, target protein downregulation lasted for only
14 days [108].
4. Functional mechanisms
Depending on the chemistry and target site, antisense oligonucleo-
tides can be used in many different ways to modulate gene expression.
Below we will discuss the major functional mechanisms that can be
used in neurodegenerative disorders (for schematic representation see
Fig. 2) where either the RNA is broken down or is altered with the use
of antisense oligonucleotides.
4.1. RNase H-mediated degradation
As described in the previous paragraph, 2′-modiﬁcations enhance
safety and pharmacologic properties of antisense oligonucleotides.
However, RNase H requires a free 2′-oxygen and oligonucleotides that
are fully 2′-modiﬁed cannot induce RNase H-mediated target RNA
downregulation [65]. To induce gene knockdown through RNase H, an
alternative strategy using gapmers has been developed (Fig. 2A and
B). A gapmer antisense oligonucleotide consists of a central DNA region
with ﬂanking 2′-modiﬁed nucleosides. Because the active site of an exo-
nuclease only binds to two or three residues at the 3′- or 5′-end, a short
stretch of 2′-modiﬁed RNA nucleosides at both ends is sufﬁcient for the
protection against exonucleases [109]. The gapmer molecule thus
beneﬁts from nuclease resistance and improved uptake from the
wings, whilst activating RNAse H owing to the gap region [65].
If the target protein has important cellular functions general down-
regulation would be detrimental. In such case speciﬁc lowering of the
mutation-containing protein is desired. Selective RNase H-mediated
degradation can be achieved using antisense oligonucleotide gapmers
targeting (1) speciﬁc point mutations [110], (2) structural differences
between wild-type and mutant mRNA [111–113], or (3) a single
nucleotide polymorphism (SNP) that is unique to the mutant RNA
[114] (Fig. 2B).
4.2. Steric hindrance
Next to RNase H-mediated breakdown of mRNA, protein levels can
also be reduced by preventing translation (Fig. 2C). Here, all nucleotides
of the antisense oligonucleotide have sugar modiﬁcations rendering
them RNase H resistant. Suppressing RNA translation to reduce protein
levels could be achieved by antisense oligonucleotides targeting the
RNA translation start site or sterically blocking the binding of RNA bind-
ing protein complexes, such as ribosomal subunits [115] (Fig. 2C).
Other antisense oligonucleotide applications that do not induce the
lowering of transcript levels are gaining more interest. The best-
known application is the manipulation of splicing [116] (Fig. 2D).
Most human genes express more than one mRNA through alternative
splicing [117] and this is an important mechanism for gene regulation.
In the brain there is a very high level of alternative splicing [118] and
disruption of normal splicing patterns can cause or modify human
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Fig. 2. Functional mechanisms of antisense oligonucleotide for central nervous system disorders. Depending on the chemistry and target site, antisense oligonucleotides can be used in
different ways to modulate gene expression: A. Antisense oligonucleotide gapmers induce RNase H-mediated breakdown of target RNA. B. RNase H-mediated breakdown by antisense
oligonucleotide gapmers targeting speciﬁc point mutations, structural differences between wild-type and mutant mRNA or a single nucleotide polymorphism (SNP) that is unique to
themutant RNA. C. Suppressing RNA translation by antisense oligonucleotides targeting the RNA translation start site or sterically blocking the binding of RNA binding protein complexes,
such as ribosomal subunits. D. Antisense oligonucleotides binding to targeting splice sites or exonic/intronic inclusion signals that will result in skipping or inclusion of the targeted exon.
SR, pre-mRNA splicing machinery.
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naturally occurring regulatory mechanism by targeting splice sites or
exonic/intronic inclusion signals that will result in skipping or inclusion
of the targeted exon and altering the RNA and protein sequence
(Fig. 2D). For neurodegenerative disorders this can have multiple appli-
cations, e.g. switching from a harmful isoform to a less harmful isoform
[119], skipping an aberrantly included exon to restore the normal
transcript [120], removing disease-causing mutations from genes
[121], or restoring the reading-frame by removing an exon with a
mutation [122].
5. Antisense oligonucleotide approaches for
neurodegenerative disorders
For non-neurodegenerative disorders several antisense oligonucleo-
tide therapies are under development with antisense-mediated exon
skipping for Duchenne muscular dystrophy the closest to clinicalapplication [123,124]. Furthermore, one of the ﬁrst repeat expansion
diseases where antisense oligonucleotidemediated RNase H dependent
degradation of mutant RNA was developed for is myotonic dystrophy
type 1 [125]. However, reaching sufﬁcient concentrations of antisense
oligonucleotides in the organ of interest and establishing sufﬁcient
high cellular uptake is a major issue. Here neurodegenerative disorders
have the advantage. After reaching the nervous system, most antisense
oligonucleotides are readily taken up by neurons and glia [3,4]. It has
been suggested that uptake occurs through nucleic acid channels
[126] but the exact mechanism of cellular uptake is still poorly under-
stood [127–129]. Once the antisense oligonucleotide has been delivered
into the nervous system, the vascular barrierswill prevent it fromenter-
ing the periphery and there will be no rapid excretion or break down by
the kidney and liver, which means that it is easier to reach clinically ef-
fective concentrations. In rodents, it was shown that the tissue half-life
of 2OMe-PS antisense oligonucleotides in peripheral tissue was around
10–65 days after IV injection [130,131]. ICV infused MOE-PS antisense
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in the brain and 145–191 days in the spinal cord [132]. This striking
difference in tissue half-life between neuronal and peripheral tissues
could be explained by lower intrinsic nuclease activity in neuronal tis-
sue compared to peripheral tissues [4], or by differences in endosome
handling between neuronal and peripheral cell types [132]. Although
antisense oligonucleotides have a long half-life they are eventually
degraded, offering the possibility to discontinue treatment [133]. For
clinical trials with long term administration it would be ideal to have
the option to terminate the treatment effect if unwanted side effects
occur. A so called antidote, or decoy, was recently applied in SMA
mice initially treated with MOE-PS antisense oligonucleotides [132].
Administration of a fully complementary oligonucleotide three weeks
after ICV injection of a therapeutic MOE-PS antisense oligonucleotide
was reported to reverse the antisense oligonucleotide-mediated
survival motor neuron 2 (SMN2) exon 7 inclusion in SMA mice [132].
For many neurodegenerative disorders it is known that certain pro-
teins are speciﬁcally upregulated, either as a primary or secondary event
in the disease process. In other disorders, proteins are not expresseddue
to mutations in a gene, or are aberrantly spliced and toxic protein
isoforms are expressed. Mutant proteins can also aggregate, which can
contribute to disease pathology. This paragraph will outline several
neurodegenerative disorders where the use of antisense oligonucleo-
tides is a promising therapeutic strategy. Examples are given where
antisense oligonucleotide treatment resulted in therapeutic beneﬁt in
animal models and/or clinical trials (Table 2).
5.1. Reducing protein expression
Next to blocking translation, antisense oligonucleotides can also
modulate splicing to introduce an out-of-frame deletion on transcript
level, resulting in nonsense-mediated decay and knockdown of target
protein expression [134]. This approach is an alternative approach to
RNase H-mediated degradation [135]. Alzheimer disease is the most
common formof dementiawhere cleavage of amyloid precursor protein
(APP) at the β-secretase and γ-secretase site causes elevated levels of
β-amyloid peptide (Aβ). This is considered a key event in the pathogen-
esis of Alzheimer disease [136]. One of the ﬁrst approaches to downreg-
ulate APP translation made use of PS antisense DNA oligonucleotides.
After tail vein injections of PS antisense oligonucleotide there was a re-
duction in APP and modest behavioural improvement in a transgenic
Alzheimer disease mouse model [19]. Whether these PS antisense
DNA oligonucleotides consisted of modiﬁed 2′ nucleosides or what the
mechanism of actionwas has not been described. Next to Aβ plaque for-
mation, another prominent feature of Alzheimer disease is aggregation
of microtubule associated protein tau to form intracellular neuroﬁbril-
lary tangles and glial tangles [137]. For Alzheimer disease and other
tauopathies, antisense oligonucleotides have been applied to reduce
expression of the tau protein [134]. Tau is encoded by the MAPT gene
and several PMOs were designed to target MAPT transcripts. In human
neuroblastoma cell lines a reduction of tau protein levels between 50%
and 80% was achieved by exon skipping to induce an out-of-frame
deletion in MAPT mRNA [134]. Antisense oligonucleotides resulting in
steric blockage of the start codon to block translation initiation were
also tested, but were found to be less efﬁcient in reducing MAPT
mRNA expression [134].
An antisense oligonucleotide therapeutic approach that is close to
clinical application in a neurodegenerative disorder has been developed
for ALS [35]. ALS is a progressive neurodegenerative disorder caused by
degeneration of motor neurons in the brain and spinal cord. This even-
tually leads to muscle weakening, twitching, and an inability to move
the arms, legs, and body [138]. Only 10% of ALS cases are familial and
about 12% of all familial cases are caused by mutations in the gene
that encodes for the enzyme superoxide dismutase 1 (SOD1) rendering
the protein toxic and prone to aggregation [139]. The antisense oligonu-
cleotides that have been used in ALS were designed to lower mRNAlevels of the SOD1 transcripts. Continuous ventricular infusion of
MOE-PS gapmer antisense oligonucleotides reduced levels of mutant
SOD1 in a rodentmodel of ALS and signiﬁcantly slowed disease progres-
sion [133]. A phase I study to test the safety of this antisense oligonucle-
otide in subjects with familial ALS with a SOD1 mutation showed no
serious adverse side effects after IT injection into the CSF [35]. A more
recent development for ALS targets the hexanucleotide repeat expan-
sion (GGGGCC) in the noncoding region of the C9ORF72 gene. This re-
peat expansion is the most common cause of familial ALS [139] and
although the underlying disease mechanism is not known, the repeat
is transcribed and leads to accumulation of repeat-containing RNA
foci in patient tissues [140]. This same repeat expansion also causes
frontotemporal dementia (FTD). FTD is characterised by degeneration
of the frontal and temporal lobes, leading to changes in personality,
behaviour, and language, resulting in death within 5 to 10 years. FTD
and ALS are closely linked and share clinical, pathological, and genetic
characteristics [141]. Various MOE-PS gapmer antisense oligonucleo-
tides, targeting exon 2 common to all C9ORF72 transcripts, and others
targeting the region in intron 1 adjacent to the repeat, reduced RNA
foci formation in motor neurons differentiated from ALS/FTD patients-
derived ﬁbroblasts and induced pluripotent stem cells [142–144].
For HD, various antisense oligonucleotides with different modiﬁca-
tions and backbones have been used to lower overall huntingtin protein
levels [145]. HD is one of the nine known polyglutamine (polyQ) disor-
ders, further consisting of the spinocerebellar ataxias ((SCAs) 1, 2, 3, 6, 7,
and 17), spinal and bulbarmuscular atrophy (SBMA) and dentatorubro-
pallidoluysian atrophy (DRPLA). PolyQ disorders are caused by a CAG
triplet repeat expansion in different genes and result in progressive
neurodegeneration with psychiatric, cognitive and motor symptoms
[146]. A prominent pathological hallmark of these diseases is the accu-
mulation of aggregated polyQ proteins in the brain [147,148]. In HD, a
generic reduction of huntingtin RNA of up to 75% usingMOE-PS gapmer
antisense oligonucleotides was found to be well tolerated in rodents
and non-human primates [32]. ICV infusion of MOE-PS antisense oligo-
nucleotides in transgenic BACHDmice for twoweeks targeting both the
human huntingtin transgene and endogenous murine huntingtin re-
sulted in reduced toxicity, extended survival, and signiﬁcant improved
motor performance up to 8 months post treatment [32]. For most of
the polyQ disorders, it is known that the wild-type polyQ-containing
proteins have important cellular functions, and therefore speciﬁc
lowering of the mutant polyQ protein levels leaving wild-type levels
unchanged, would be favoured over a generic downregulation.
Antisense oligonucleotide-mediated reduction of disease-speciﬁc
upregulated proteins has been proposed as potential treatment formul-
tiple sclerosis (MS). MS is an autoimmune disease of the CNS where
multifocal inﬁltration of autoreactive T lymphocytes across the BBB
takes place. Lymphocytes in MS patients display high levels of α-4
integrin on their surface [149] and this plays an important role in lym-
phocyte migration to sites of inﬂammation [150]. Decreasing leukocyte
trafﬁcking into various organs has been successful usingmonoclonal an-
tibodies againstα-4 integrin [151]. In a commonly usedmousemodel of
MS, the experimental autoimmune encephalomyelitis model, antisense
oligonucleotide-induced blocking of α-4 integrin expression reduced
the incidence and severity of paralytic symptoms [152]. The 20-mer an-
tisense oligonucleotides with MOE modiﬁcations and a PS backbone
were designed to target a sequence just 3′ of the translation start site
of themurineα-4 integrin mRNA to block its translation. Subcutaneous
daily injections reduced α-4 integrin surface expression. Although the
site of action of this particular antisense oligonucleotide is unknown, it
is thought that α-4 integrin levels are reduced in peripheral lymphoid
tissue and this prevents trafﬁcking of activated mononuclear cells into
the brain and spinal cord [152].
Reducing protein expression by antisense oligonucleotides was re-
cently also shown as proof-of-principle for patients with Creutzfeldt–
Jakob disease (CJD) [153]. CJD is caused by a conformational change
of the harmless cellular prion protein (PrPc) into an infectious and
Table 2
Antisense oligonucleotide approaches for neurodegenerative disorders.
Disease Target gene Oligonucleotide chemistry Mechanism Organism Administration Molecular effect Phenotypic effect Clinical/preclinical Reference
SMA SMN2 MOE-PS Splicing modulation SMA patients Intrathecal Not tested. Good CSF distribution, no
serious adverse events
NA Phase 1 clinical [192]
SMN2 MOE-PS, PMO and 2′OMe-PS Splicing modulation SMAmice and NH
primates
ICV in mice, intrathecal
in NH primates
Mice: up to 3.5 fold change in transcript
ratio
Primate: predicted therapeutic dose
NA Preclinical [132]
SMN2 PMO Splicing modulation SMA mouse ICV 8 fold increase SMN2 protein level Lifespan extended from
13 to 54 days
Preclinical [189]
SMN2 PMO and vivo-PMO Splicing modulation SMA mouse ICV and SC 11 fold increase transcript ratio Lifespan increased by 60
days
Preclinical [103]
SMN2 PMO Splicing modulation SMA mouse ICV 6 fold increase full length SMN2 transcript,
and 3-fold increase protein
Lifespan extended from
15 to N100 days
Preclinical [102]
SMN2 2OMe-PS, bifunctional Splicing modulation +
recruitment splicing factors
SMA mouse ICV 3.5 fold increase SMN protein Lifespan extended by 8
days
Preclinical [186]
SMN2 MOE-PS Splicing modulation SMA mouse ICV and SC ICV: 83% exon inclusion in brain
SC: 47% exon inclusion in brain
ICV: lifespan extended
to 16 days
ICV + IP: lifespan
extended to 173 days
Preclinical [193]
ALS SOD1 MOE-PS gapmer RNase-H mediated degradation ALS patients Intrathecal Not tested. No serious adverse events. NA Phase 1 clinical [35]
AChE Oligodeoxynucleotide, 3
3′-nucleosides 2′Omemodiﬁed
RNAse-H mediated degradation SOD1 mouse IP Higher motor neuron count Lifespan extended by
10 days
Preclinical [194]
C9ORF72 MOE-PS gapmer and
2OMe-PS
RNase-H mediated degradation or
steric hindrance of GGGGCC repeat
iPSC differentiated
neurons
NA Reduction in RNA foci and RNA binding
protein aggregation with both strategies
Mitigation
excitotoxicity
Preclinical [142]
C9ORF72 MOE-PS gapmer RNase-H mediated degradation Mouse ICV Reduction C9ORF72 by 65% in brain and
spinal cord.
No behavioural deﬁcits
induced
Preclinical [143]
SOD1 MOE-PS gapmer RNase-H mediated degradation SOD1 rats ICV SOD1 protein reduction by ~40% NA Preclinical [195]
SOD1 MOE-PS gapmer RNase-H mediated degradation SOD1 rats and rhesus
monkey
ICV Rat: 60% downregulation SOD1 protein Lifespan extended by 10
days
Preclinical [133]
GluR3 PNA Not described SOD1 mouse IP No effect seen at protein level in spinal cord Lifespan extended by
10%
Preclinical [196]
p75NTR PNA Translational arrest SOD1 mouse IP Apparent p75NTR downregulation in spinal
cord, though not quantiﬁed
Lifespan extended by
~10 days
Preclinical [191]
HD Mutant HTT MOE-PS and cEt-PS gapmers RNase-H mediated degradation neuronal culture bath application Almost complete downregulation mutant
htt protein
NA Preclinical [157]
Mutant HTT MOE-PS and cEt-PS gapmers RNase-H mediated degradation HD mouse ICV 90% reduction mutant htt protein NA Preclinical [87]
Mutant HTT MOE-PS and cEt-PS gapmers RNase-H mediated degradation HD mouse ICV 90% reduction mutant htt protein NA Preclinical [159]
HTT MOE-PS gapmer RNase-H mediated degradation HD mouse ICV 50% reduction mutant htt protein Correction of motor and
psychiatric phenotypes
Preclinical [197]
HTT MOE-PS gapmer RNase-H mediated degradation HDmice, Rhesus
monkey
ICV in mice, intrathecal
in monkey
Mouse: up to 75% reduction htt protein
Monkey: 60% reduction HTT RNA
Mouse: motor
coordination reverted to
normal levels
Preclinical [32]
HTT MOE-PS and cEt-PS gapmers RNase-H mediated degradation HD mice Locally in striatum 50% downregulation mutant htt protein NA Preclinical [158]
HTT PNA and LNA Unknown mechanism, CAG repeat
targeting
Fibroblasts Transfection Up to ~80% allele speciﬁc downregulation
mutant htt protein
NA Preclinical [112]
HTT 2OMe-PS Splicing modulation Mouse Locally in brain 25% exon skipping HTT mRNA NA Preclinical [175]
AD Mutated APP MOE gapmer RNase-H mediated degradation AD mouse ICV AChE level almost back to normal NA Preclinical [110]
GSK-3β PS DNA RNase-H mediated degradation AD mouse ICV ~25% reduction GSK-3β Improved learning and
memory
Preclinical [198]
Creutzfeldt–Jakob PrPc MOE-PS gapmer RNase-H mediated degradation Prion infected mouse ICV Disease causing prion protein reduced by
90%
Incubation period
prolonged by 2 months
Preclinical [153]
SCA3 Ataxin-3 2OMe-PS Splicing modulation Mouse ICV 40% exon skipping of ataxin-3 mRNA NA Preclinical [121]
Menkes disease ATP7A PMO Splicing modulation Zebraﬁsh Microinjection ATP7A protein restored to 35% of wildtype
levels
Melanin pigmentation
and notochord
abnormalities rescued
Preclinical [168]
FTD Tau 2OMe-PS and PNA Splicing modulation Neuroblastoma cells
with tau minigene
Transfection Up to 4 fold change in exon inclusion NA Preclinical [172]
2OMe, 2′-O-methyl; AChE, acetylcholinesterase; AD, Alzheimer disease; ALS, amyotrophic lateral sclerosis; APP, amyloid precursor protein; ATP7A, copper-transporting ATPase 1; cEt, S-constrained-ethyl; CJD, Creutzfeldt–Jakob disease; CSF, cere-
brospinalﬂuid; FTD, frontotemporal dementia; GluR3, glutamate receptor subunit 3; GSK-3β, glycogen synthase kinase 3; HD, Huntington disease;HTT, huntingtin; ICV, Intracerebroventricular; IP, intraperitoneal; iPSC, inducedpluripotent stemcells;
LNA, locked nucleic acid; NA, not assessed; NH, non-human; MOE, 2′-O-methoxy-ethyl; p75NTR, p75 neurotrophin receptor; PMO, phosphorodiamidate morpholino oligomer; PNA, peptide nucleic acid; PrPc, cellular prion protein; PS, phosphoro-
thioate; SC, subcutaneous; SCA3, spinocerebellar ataxia type 3; SMA, spinal muscular atrophy; SMN2, survival of motor neuron 2; SOD1, superoxide dismutase 1.
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sition of extracellular aggregated prion proteins. The infectious PrPSc has
theunique characteristic that it spreads throughout the brain and can be
transmitted between people as well as between different species [154].
ICV infusion in PrPSc infected mice of MOE-PS gapmer antisense oligo-
nucleotides for 14 days resulted in reduced PrPc as well as reduced
disease-causing PrPSc levels [153]. This reduction in disease-causing
PrPSc is probably not due to decreased PrPc, but due to a, yet unknown,
anti-prion action of PS modiﬁed antisense oligonucleotides [155,156].
5.2. Speciﬁcally targeting the mutant transcript
If a therapeutic target protein has important cellular functions and
general downregulation would be detrimental, a speciﬁc lowering of
the mutation-containing protein is desired. As described previously,
there are several ways to speciﬁcally lower mutant transcript and/or
mutant protein levels using antisense oligonucleotides.
Targeting the repeat expansion directly has been proposed as
potential treatment for ALS/FTD [142,143]. Binding of antisense oligo-
nucleotides to intronic sequences exclusively linked to the GGGGCC
hexanucleotide repeat expansion [143] or to the repeat directly [142]
resulted in reduced RNA foci formation in ALS/FTD patient-derived
neuronal cells. To achieve GGGGCC repeat speciﬁc targeting two
mechanisms were proposed: 1) 2OMe-PS antisense oligonucleotides
that disrupt the hairpin structure of the expansion and prevents RNA
binding proteins to sequester to the GGGGCC repeat, and 2) MOE-PS
gapmer antisense oligonucleotides that bind to the repeat and target
the mutant C9ORF72 transcripts for RNase H-mediated RNA degradation
[142].
For polyQ disorders the method that has frequently been used is
targeting of the common denominator, the expanded CAG repeat. The
mechanism behind this selective silencing is either due to structural
differences between wild-type and expanded CAG-enclosing mRNA,
or because a larger number of CAGs in the expanded repeat provides
more binding possibilities for CAG-targeting oligonucleotides. Single
stranded PNAs, LNAs, 2OMe-PS, and PMO antisense oligonucleotides
targeting CAG repeats have all been used to speciﬁcally reduce expand-
ed CAG-containing transcripts in vitro in patient-derived ﬁbroblasts
[111–113] and in vivo in a transgenic and a knock-in HD mouse
model [113]. Although results look promising, some of the antisense
oligonucleotides described here only show proper allele-speciﬁcity at
longer CAG repeat lengths that are not very frequent in the patient pop-
ulation. Furthermore, although initial results do not show unwanted
downregulation of other CAG-containing transcripts [111], this needs
to be investigated further.
Another way to design a molecule that can distinguish between the
wild-type and expanded CAG-containingmRNA is to target a SNP that is
located on the mutant transcript [114,157]. Chimeric MOE-PS DNA and
cEt antisense oligonucleotideswere shown to selectively reducemutant
huntingtin expression in patient-derived cells [158,159]. A single ICV in-
jection of chimeric cEt antisense oligonucleotides in a humanized HD
mouse model resulted in reduction in mutant huntingtin expression
up to 36 weeks post treatment [87]. Although the allele speciﬁcity
with SNP targeting antisense oligonucleotides is very promising, there
are some limitations. The diversity of SNPs within patient populations
would make it necessary to developmultiple oligonucleotides. Further-
more, this approach is not applicable for HD patients that do not exhibit
heterozygosity for the most frequent SNPs in the coding region of the
HTT gene.
Another mutant-speciﬁc reduction of neurodegenerative disease-
causing protein expression makes use of antisense oligonucleotides
that target point mutations. For instance, point mutations near the β-
secretase site in the human gene for APP lead to a dominantly inherited
form of Alzheimer disease [160]. In a transgenic mouse model of
Alzheimer disease containing this mutation, translation of the APP
mRNA was blocked by MOE-PS gapmer antisense oligonucleotidesthat bind speciﬁcally to the mutated β-secretase site [110]. Repeated
injections into the third ventricle (once a week for 4 weeks) reduced
the levels of toxic Aβ, indicating that this could be a possible strategy
to treat familial Alzheimer disease [110].
5.3. Restoring protein expression — interfering with pre-mRNA splicing
The most prominent application of protein modiﬁcation through
antisense oligonucleotides interfering with pre-mRNA splicing has
been researched for SMA. SMA is an autosomal recessive neuromuscular
disorder caused by dysfunction and loss of motor neurons in the anteri-
or horn of the spinal cord and lower brain stem. The underlying cause of
SMA is a homozygous deletion of SMN1. SMN1 depletion is not lethal
because of the presence of the almost identical SMN2 gene. However,
the majority of SMN2 mRNA transcripts lack exon 7, due to a silent
mutation within this exon. This reduces the inclusion of exon 7 which
results in a truncated protein and reduced expression of functional
SMN protein [161]. Current therapeutic strategies are aimed at modu-
lating the splicing of SMN2 by blocking exonic splicing silencers (ESS)
or intronic splicing silencers (ISS), thereby increasing exon 7 inclusion.
Transfecting ﬁbroblasts with an antisense oligonucleotide (termed
ISS-N1) blocking an ISS in intron 7 of SMN2 resulted in inclusion of
SMN2 exon 7 [120]. Improved efﬁcacy of the antisense oligonucleotide
was achieved by incorporation of a uniform MOE chemistry. A single
injection of this MOE-PS antisense oligonucleotide into the cerebral
ventricles in a severemousemodel of SMA showed increased exon 7 in-
clusion and SMN protein levels in the spinal cord resulting in increased
muscle size and strength [162]. An increased exon 7 inclusion has also
been achieved by 2OMe-PS antisense oligonucleotides targeting the 3′
splice site region of exon 8 [163]. These 2OMe-PS antisense oligonucle-
otides were found to result in exon 7 inclusion and elevated SMN
protein expression levels in vivo [71,164]. A phase I clinical trial has
been completed for SMA using IT injections of the MOE-PS antisense
oligonucleotide targeting exon 7 inclusion [36]. In the high dose treated
patients, SMN protein levels in the CSF more than doubled and these
children showed increased muscle function scores up to 14 months
after the injection [165], although these results should be interpreted
with caution because this was an open label study. Currently a phase 2
trial is ongoingwith 6mg or 12mg doses of MOE-PS antisense oligonu-
cleotide administered IT on days 1, 15 and 85 [166]. Interim results
show that the MOE-modiﬁed antisense oligonucleotide is also well
tolerated after repeated injections [166].
Restoration of protein expression using antisense oligonucleotides is
also applied to ataxia–telangiectasia. The most debilitating feature of
ataxia–telangiectasia is the progressive loss of Purkinje cells in the
cerebellum and the accompanying progressive ataxia due to mutations
in the ATM gene (ataxia–telangiectasia mutated). The majority of
mutations in the ATM gene are splice site substitutions that result in
the absence of full-length ATM protein [167]. CPP PMOs targeting
prototypic ATM splicing mutations that activated cryptic splicing sites
restored ATM protein expression in cells [122]. Whilst the CPP PMO
was shown to distribute throughout the mouse brain following
repeated IV injection, no phenotypical changes were observed [26].
In a Menkes disease zebraﬁsh model, correction of the disease
phenotypewas observed after PMOmicroinjection [168]. The fatal neu-
rodegenerative disorder Menkes disease is caused by varied mutations
in the ATP7A gene, resulting in loss-of-function of the transmembrane
copper-transporting P-type ATPase [169]. TheMenkes disease zebraﬁsh
had mutations at the 3′ and 5′ splice sites of the ATP7A orthologue,
resulting in activation of cryptic splice sites and loss of the protein's
ATPase function [168]. Various PMOs were investigated for their ability
to rescue aberrant splicing [168]. However, mutations are distributed
throughout the ATP7A gene [170] meaning that many different
antisense oligonucleotides would have to be developed to treat all
patients and the clinical use of antisense oligonucleotides for Menkes
disease patients is currently limited.
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Antisense oligonucleotides are also used to remove neurodegenera-
tive disease-causing mutations from genes at the RNA level. Antisense
oligonucleotides have been applied to correct the ratio of tau protein
isoforms as potential treatment for FTD [171,172]. Tau interacts with
microtubules through its microtubule binding repeat domains encoded
by exons 9 to 12 [173]. Alternative splicing of exon 10 produces tau
isoforms without exon 10 (3R) or with exon 10 (4R). In healthy
human brain the ratio of 4R to 3R tau is generally around 1. Due to 5′
splice site mutations in FTD patients, the ratio 4R to 3R tau is shifted
towards more exon 10-containing 4R [174], resulting in the formation
of intracellular neuroﬁbrillary tangles. Co-transfectingMAPTminigenes
with 2OMe-PS [171] or PNA [172] antisense oligonucleotides directed
against the 5′ splice site of exon 10 prevented exon 10 inclusion and
shifted the 4R to 3R tau ratio towards more 3R tau levels.
In polyQ disorders, exon skipping is applied to modify polyQ
proteins to prevent their toxic gain-of-function. In SCA3, reduction of
polyQ toxicity was proposed by removal of the toxic polyQ repeat
from the ataxin-3 protein [121]. By exclusion of exon 9 and the CAG-
enclosing exon 10 from the ataxin-3 pre-mRNA using 2OMe-PS
antisense oligonucleotides, a modiﬁed ataxin-3 protein was formed
that lacked the polyQ repeat and retained important wild-type func-
tions [121]. For HD, a more indirect antisense oligonucleotide approach
to reduce protein toxicity was proposed [175]. Several studies have
implicated the importance of proteolytic cleavage of mutant huntingtin
in HD pathogenesis and it is generally accepted that N-terminal
huntingtin fragments are more toxic than full-length protein [176–178].
Transfection of 2OMe-PS antisense oligonucleotides resulted in skipping
of exon 12 in huntingtin pre-mRNA and the appearance of a shorter
huntingtin protein [175]. In the 2OMe-PS antisense oligonucleotide treat-
ed ﬁbroblasts, after proteolytic cleavage less 586 amino acid N-terminal
huntingtin fragments implicated in HD toxicity was formed [175]. After
a single ICV injection of murine 2OMe-PS antisense oligonucleotides,
exon skipping of huntingtin and ataxin-3 was shown in the cerebellum
[121] and striatum [175] of control mice. The advantage of this exon
skipping approach is that there is no reduction in protein levels and the
wild-type functions of the proteins likely remain largely unchanged.
6. Conclusion
The recent advances towards the clinical application of antisense
oligonucleotides for neurodegenerative disorders are encouraging but
safe delivery, long term efﬁcacy and side effects of prolonged treatment
still need to be assessed. Also, most studies have been performed in
small animals and delivering high enough doses of antisense oligonu-
cleotides throughout the much larger human brain will be a challenge.
However, the widespread cellular uptake into brain cells is a major
advantage over peripheral antisense oligonucleotide applications. The
ease of delivery of modiﬁed antisense oligonucleotides seems to be
linked with a lack of any major adverse side effects, making antisense
oligonucleotides suitable candidates as potential treatment for
neurodegenerative diseases. Completed clinical trials on antisense
oligonucleotide-mediated therapies into the CSF reported thus far
have been successful and no major adverse events were reported
[35,165] bringing this application closer to offer relief to many patients
and families that so far had to do without effective treatment.
Acknowledgements
The authorswould like to acknowledge Annemieke Aartsma-Rus for
critically reading the manuscript. We also thank the following agencies
for their funding support: AFMTéléthon no. 17295 (France), ZonMw
no. 40-41900-98-018 (The Netherlands), Hersenstichting/ Brugling
Fund BG2013-03 (The Netherlands), AtaxiaUK (United Kingdom),
patiëntenvereniging Autosomaal Dominante Cerebellaire Ataxia(ADCA) (the Netherlands), and the European Community’s Seventh
Framework Programme (FP7/2007-2013) under grant agreement no.
2012-305121“Integrated European –omics research project for diagno-
sis and therapy in rare neuromuscular and neurodegenerative diseases
(NEUROMICS)”.
References
[1] M.L. Stephenson, P.C. Zamecnik, Inhibition of Rous sarcoma viral RNA translation
by a speciﬁc oligodeoxyribonucleotide, Proc. Natl. Acad. Sci. U. S. A. 75 (1978)
285–288.
[2] P. Jarver, L. O'Donovan, M.J. Gait, A chemical view of oligonucleotides for exon
skipping and related drug applications, Nucleic Acid Ther. 24 (2014) 37–47.
[3] M. Butler, C.S. Hayes, A. Chappell, S.F. Murray, T.L. Yaksh, X.Y. Hua, Spinal distribu-
tion and metabolism of 2′-O-(2-methoxyethyl)-modiﬁed oligonucleotides after
intrathecal administration in rats, Neuroscience 131 (2005) 705–715.
[4] L. Whitesell, D. Geselowitz, C. Chavany, B. Fahmy, S. Walbridge, J.R. Alger, L.M.
Neckers, Stability, clearance, and disposition of intraventricularly administered
oligodeoxynucleotides: implications for therapeutic application within the central
nervous system, Proc. Natl. Acad. Sci. U. S. A. 90 (1993) 4665–4669.
[5] M.M. Maxwell, RNAi applications in therapy development for neurodegenerative
disease, Curr. Pharm. Des. 15 (2009) 3977–3991.
[6] M.S. Alavijeh, M. Chishty, M.Z. Qaiser, A.M. Palmer, Drug metabolism and pharma-
cokinetics, the blood–brain barrier, and central nervous system drug discovery,
NeuroRx 2 (2005) 554–571.
[7] J. Bernacki, A. Dobrowolska, K. Nierwinska, A. Malecki, Physiology and pharmaco-
logical role of the blood–brain barrier, Pharmacol. Rep. 60 (2008) 600–622.
[8] A.M. Palmer, The blood–brain barrier, Neurobiol. Dis. 37 (2010) 1–2.
[9] V. Bartanusz, D. Jezova, B. Alajajian,M. Digicaylioglu, The blood–spinal cord barrier:
morphology and clinical implications, Ann. Neurol. 70 (2011) 194–206.
[10] B. Engelhardt, L. Sorokin, The blood–brain and the blood–cerebrospinal ﬂuid
barriers: function and dysfunction, Semin. Immunopathol. 31 (2009) 497–511.
[11] S. Ge, J.S. Pachter, Isolation and culture of microvascular endothelial cells from
murine spinal cord, J. Neuroimmunol. 177 (2006) 209–214.
[12] O. Tomkins, O. Friedman, S. Ivens, C. Reiffurth, S. Major, J.P. Dreier, U. Heinemann,
A. Friedman, Blood–brain barrier disruption results in delayed functional and
structural alterations in the rat neocortex, Neurobiol. Dis. 25 (2007) 367–377.
[13] E.A. Winkler, J.D. Sengillo, A.P. Sagare, Z. Zhao, Q. Ma, E. Zuniga, Y. Wang, Z. Zhong,
J.S. Sullivan, J.H. Grifﬁn, et al., Blood–spinal cord barrier disruption contributes to
early motor–neuron degeneration in ALS-model mice, Proc. Natl. Acad. Sci. U. S.
A. 111 (2014) E1035–E1042.
[14] G. Gerebtzoff, A. Seelig, In silico prediction of blood–brain barrier permeation using
the calculated molecular cross-sectional area as main parameter, J. Chem. Inf.
Model. 46 (2006) 2638–2650.
[15] W.M. Pardridge, Biopharmaceutical drug targeting to the brain, J. Drug Target. 18
(2010) 157–167.
[16] S. Agrawal, J. Temsamani, J.Y. Tang, Pharmacokinetics, biodistribution, and stability
of oligodeoxynucleotide phosphorothioates inmice, Proc. Natl. Acad. Sci. U. S. A. 88
(1991) 7595–7599.
[17] W.A. Banks, S.A. Farr, W. Butt, V.B. Kumar, M.W. Franko, J.E. Morley, Delivery across
the blood–brain barrier of antisense directed against amyloid beta: reversal of
learning and memory deﬁcits in mice overexpressing amyloid precursor protein,
J. Pharmacol. Exp. Ther. 297 (2001) 1113–1121.
[18] P.A. Cossum, H. Sasmor, D. Dellinger, L. Truong, L. Cummins, S.R. Owens, P.M.
Markham, J.P. Shea, S. Crooke, Disposition of the 14C-labeled phosphorothioate
oligonucleotide ISIS 2105 after intravenous administration to rats, J. Pharmacol.
Exp. Ther. 267 (1993) 1181–1190.
[19] S.A. Farr, M.A. Erickson, M.L. Niehoff, W.A. Banks, J.E. Morley, Central and peripher-
al administration of antisense oligonucleotide targeting amyloid-beta protein
precursor improves learning and memory and reduces neuroinﬂammatory
cytokines in Tg2576 (AbetaPPswe) mice, J. Alzheimers Dis. 40 (2014) 1005–1016.
[20] W.M. Pardridge, Blood–brain barrier delivery, Drug Discov. Today 12 (2007) 54–61.
[21] H.J. Lee, R.J. Boado, D.A. Braasch, D.R. Corey, W.M. Pardridge, Imaging gene expres-
sion in the brain in vivo in a transgenic mouse model of Huntington's disease with
an antisense radiopharmaceutical and drug-targeting technology, J. Nucl. Med. 43
(2002) 948–956.
[22] S. Kozlu, S. Caban, F. Yerlikaya, E. Fernandez-Megia, R. Novoa-Carballal, R. Riguera,
M. Yemisci, Y. Gursoy-Ozdemir, T. Dalkara, P. Couvreur, et al., An aquaporin 4
antisense oligonucleotide loaded, brain targeted nanoparticulate system design,
Pharmazie 69 (2014) 340–345.
[23] D. Derossi, A.H. Joliot, G. Chassaing, A. Prochiantz, The third helix of the
Antennapedia homeodomain translocates through biological membranes, J. Biol.
Chem. 269 (1994) 10444–10450.
[24] T. Kang, X. Gao, J. Chen, Harnessing the capacity of cell-penetrating peptides for
drug delivery to the central nervous system, Curr. Pharm. Biotechnol. 15 (2014)
220–230.
[25] S. El-Andaloussi, T. Holm, U. Langel, Cell-penetrating peptides: mechanisms and
applications, Curr. Pharm. Des. 11 (2005) 3597–3611.
[26] L. Du, R. Kayali, C. Bertoni, F. Fike, H. Hu, P.L. Iversen, R.A. Gatti, Arginine-rich
cell-penetrating peptide dramatically enhances AMO-mediated ATM aberrant
splicing correction and enables delivery to brain and cerebellum, Hum. Mol.
Genet. 20 (2011) 3151–3160.
[27] A. Amantana, H.M. Moulton, M.L. Cate, M.T. Reddy, T. Whitehead, J.N. Hassinger,
D.S. Youngblood, P.L. Iversen, Pharmacokinetics, biodistribution, stability and
100 M.M. Evers et al. / Advanced Drug Delivery Reviews 87 (2015) 90–103toxicity of a cell-penetrating peptide–morpholino oligomer conjugate, Bioconjug.
Chem. 18 (2007) 1325–1331.
[28] H.M. Moulton, J.D. Moulton, Morpholinos and their peptide conjugates: therapeutic
promise and challenge for Duchenne muscular dystrophy, Biochim. Biophys. Acta
1798 (2010) 2296–2303.
[29] L. Alvarez-Erviti, Y. Seow, H. Yin, C. Betts, S. Lakhal, M.J. Wood, Delivery of siRNA to
the mouse brain by systemic injection of targeted exosomes, Nat. Biotechnol. 29
(2011) 341–345.
[30] H. Valadi, K. Ekstrom, A. Bossios, M. Sjostrand, J.J. Lee, J.O. Lotvall, Exosome-
mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic
exchange between cells, Nat. Cell Biol. 9 (2007) 654–659.
[31] P. Kumar, H. Wu, J.L. McBride, K.E. Jung, M.H. Kim, B.L. Davidson, S.K. Lee, P.
Shankar, N. Manjunath, Transvascular delivery of small interfering RNA to the cen-
tral nervous system, Nature 448 (2007) 39–43.
[32] H.B. Kordasiewicz, L.M. Stanek, E.V. Wancewicz, C. Mazur, M.M. McAlonis, K.A.
Pytel, J.W. Artates, A. Weiss, S.H. Cheng, L.S. Shihabuddin, et al., Sustained
therapeutic reversal of Huntington's disease by transient repression of huntingtin
synthesis, Neuron 74 (2012) 1031–1044.
[33] K. Margetis, S. Korﬁas, N. Boutos, S. Gatzonis, M. Themistocleous, A. Siatouni, Z.
Dalivigka, T. Flaskas, G. Stranjalis, E. Boviatsis, et al., Intrathecal baclofen therapy
for the symptomatic treatment of hereditary spastic paraplegia, Clin. Neurol.
Neurosurg. 123 (2014) 142–145.
[34] A. Ver Donck, J.H. Vranken, M. Puylaert, S. Hayek, N. Mekhail, J. Van Zundert,
Intrathecal drug administration in chronic pain syndromes, Pain Pract. 14 (2014)
461–476.
[35] T.M. Miller, A. Pestronk, W. David, J. Rothstein, E. Simpson, S.H. Appel, P.L. Andres,
K. Mahoney, P. Allred, K. Alexander, et al., An antisense oligonucleotide against
SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral
sclerosis: a phase 1, randomised, ﬁrst-in-man study, Lancet Neurol. 12 (2013)
435–442.
[36] Isis Pharmaceuticals, An Open-label Safety, Tolerability, and Dose-range Finding
Study of ISIS SMNRx in Patients With Spinal Muscular Atrophy, ClinicalTrials. gov
NCT01494701, 2011.
[37] M.A. Curtis, M. Kam, U. Nannmark, M.F. Anderson,M.Z. Axell, C.Wikkelso, S. Holtas,
W.M. van Roon-Mom, T. Bjork-Eriksson, C. Nordborg, et al., Human neuroblastsmi-
grate to the olfactory bulb via a lateral ventricular extension, Science 315 (2007)
1243–1249.
[38] A. Claxton, L.D. Baker, C.W. Wilkinson, E.H. Trittschuh, D. Chapman, G.S. Watson, B.
Cholerton, S.R. Plymate, M. Arbuckle, S. Craft, Sex and ApoE genotype differences in
treatment response to two doses of intranasal insulin in adults with mild cognitive
impairment or Alzheimer's disease, J. Alzheimers Dis. 35 (2013) 789–797.
[39] T. Kanazawa, F. Akiyama, S. Kakizaki, Y. Takashima, Y. Seta, Delivery of siRNA to the
brain using a combination of nose-to-brain delivery and cell-penetrating peptide-
modiﬁed nano-micelles, Biomaterials 34 (2013) 9220–9226.
[40] R. Hashizume, T. Ozawa, S.M. Gryaznov, A.W. Bollen, K.R. Lamborn, W.H. Frey, D.F.
Deen, New therapeutic approach for brain tumors: intranasal delivery of
telomerase inhibitor GRN163, Neuro Oncol. 10 (2008) 112–120.
[41] N. Dias, C.A. Stein, Antisense oligonucleotides: basic concepts and mechanisms,
Mol. Cancer Ther. 1 (2002) 347–355.
[42] P.S. Eder, R.J. DeVine, J.M. Dagle, J.A. Walder, Substrate speciﬁcity and kinetics of
degradation of antisense oligonucleotides by a 3′ exonuclease in plasma, Antisense
Res. Dev. 1 (1991) 141–151.
[43] J.M. Dagle, D.L. Weeks, J.A. Walder, Pathways of degradation and mechanism of
action of antisense oligonucleotides in Xenopus laevis embryos, Antisense Res.
Dev. 1 (1991) 11–20.
[44] E. De Clercq, E. Eckstein, T.C. Merigan, Interferon induction increased through
chemical modiﬁcation of a synthetic polyribonucleotide, Science 165 (1969)
1137–1139.
[45] J.M. Campbell, T.A. Bacon, E. Wickstrom, Oligodeoxynucleoside phosphorothioate
stability in subcellular extracts, culture media, sera and cerebrospinal ﬂuid,
J. Biochem. Biophys. Methods 20 (1990) 259–267.
[46] P.L. Iversen, S. Zhu, A. Meyer, G. Zon, Cellular uptake and subcellular distribution of
phosphorothioate oligonucleotides into cultured cells, Antisense Res. Dev. 2 (1992)
211–222.
[47] S. Ogawa, H.E. Brown, H.J. Okano, D.W. Pfaff, Cellular uptake of intracerebrally
administered oligodeoxynucleotides in mouse brain, Regul. Pept. 59 (1995)
143–149.
[48] H. Wu,W.F. Lima, H. Zhang, A. Fan, H. Sun, S.T. Crooke, Determination of the role of
the human RNase H1 in the pharmacology of DNA-like antisense drugs, J. Biol.
Chem. 279 (2004) 17181–17189.
[49] C.F. Bennett, E.E. Swayze, RNA targeting therapeutics: molecular mechanisms of
antisense oligonucleotides as a therapeutic platform, Annu. Rev. Pharmacol.
Toxicol. 50 (2010) 259–293.
[50] S.M. Cerritelli, R.J. Crouch, Ribonuclease H: the enzymes in eukaryotes, FEBS J. 276
(2009) 1494–1505.
[51] J.W. Jaroszewski, V. Clausen, J.S. Cohen, O. Dahl, NMR investigations of duplex
stability of phosphorothioate and phosphorodithioate DNA analogues modiﬁed
in both strands, Nucleic Acids Res. 24 (1996) 829–834.
[52] A.A. Levin, A review of the issues in the pharmacokinetics and toxicology of
phosphorothioate antisense oligonucleotides, Biochim. Biophys. Acta 1489
(1999) 69–84.
[53] D.A. Brown, S.H. Kang, S.M. Gryaznov, L. DeDionisio, O. Heidenreich, S. Sullivan, X. Xu,
M.I. Nerenberg, Effect of phosphorothioate modiﬁcation of oligodeoxynucleotides on
speciﬁc protein binding, J. Biol. Chem. 269 (1994) 26801–26805.
[54] M.A. Guvakova, L.A. Yakubov, I. Vlodavsky, J.L. Tonkinson, C.A. Stein, Phosphoro-
thioate oligodeoxynucleotides bind to basic ﬁbroblast growth factor, inhibit itsbinding to cell surface receptors, and remove it from low afﬁnity binding sites on
extracellular matrix, J. Biol. Chem. 270 (1995) 2620–2627.
[55] W.M. Galbraith, W.C. Hobson, P.C. Giclas, P.J. Schechter, S. Agrawal, Complement
activation and hemodynamic changes following intravenous administration of
phosphorothioate oligonucleotides in the monkey, Antisense Res. Dev. 4 (1994)
201–206.
[56] A. Rifai, W. Brysch, K. Fadden, J. Clark, K.H. Schlingensiepen, Clearance kinetics,
biodistribution, and organ saturability of phosphorothioate oligodeoxynucleotides
in mice, Am. J. Pathol. 149 (1996) 717–725.
[57] T.A. Watanabe, R.S. Geary, A.A. Levin, Plasma protein binding of an antisense
oligonucleotide targeting human ICAM-1 (ISIS 2302), Oligonucleotides 16 (2006)
169–180.
[58] J.A. Phillips, S.J. Craig, D. Bayley, R.A. Christian, R. Geary, P.L. Nicklin, Pharmacokinetics,
metabolism, and elimination of a 20-mer phosphorothioate oligodeoxynucleotide
(CGP 69846A) after intravenous and subcutaneous administration, Biochem.
Pharmacol. 54 (1997) 657–668.
[59] S.M. Freier, K.H. Altmann, The ups and downs of nucleic acid duplex stability:
structure–stability studies on chemically-modiﬁed DNA:RNA duplexes, Nucleic
Acids Res. 25 (1997) 4429–4443.
[60] P. Lubini, W. Zurcher, M. Egli, Stabilizing effects of the RNA 2′-substituent: crystal
structure of an oligodeoxynucleotide duplex containing 2′-O-methylated
adenosines, Chem. Biol. 1 (1994) 39–45.
[61] R.A. McKay, L.J. Miraglia, L.L. Cummins, S.R. Owens, H. Sasmor, N.M. Dean,
Characterization of a potent and speciﬁc class of antisense oligonucleotide in-
hibitor of human protein kinase C-alpha expression, J. Biol. Chem. 274 (1999)
1715–1722.
[62] R.S. Geary, T.A. Watanabe, L. Truong, S. Freier, E.A. Lesnik, N.B. Siouﬁ, H. Sasmor, M.
Manoharan, A.A. Levin, Pharmacokinetic properties of 2′-O-(2-methoxyethyl)-
modiﬁedoligonucleotide analogs in rats, J. Pharmacol. Exp. Ther. 296 (2001) 890–897.
[63] Q. Zhao, J. Temsamani, P.L. Iadarola, Z. Jiang, S. Agrawal, Effect of different
chemically modiﬁed oligodeoxynucleotides on immune stimulation, Biochem.
Pharmacol. 51 (1996) 173–182.
[64] H.S. Peng, V. Livanov, W. Zhang, J. Li, T. Lesher, Modiﬁcation of phosphorothioate
oligonucleotides yields potent analogs with minimal toxicity for antisense
experiments in the CNS, Brain Res. Mol. Brain Res. 62 (1998) 1–11.
[65] B.P. Monia, E.A. Lesnik, C. Gonzalez, W.F. Lima, D. McGee, C.J. Guinosso, A.M.
Kawasaki, P.D. Cook, S.M. Freier, Evaluation of 2′-modiﬁed oligonucleotides
containing 2′-deoxy gaps as antisense inhibitors of gene expression, J. Biol.
Chem. 268 (1993) 14514–14522.
[66] G. Liebsch, R. Landgraf, M. Engelmann, P. Lorscher, F. Holsboer, Differential
behavioural effects of chronic infusion of CRH 1 and CRH 2 receptor antisense
oligonucleotides into the rat brain, J. Psychiatr. Res. 33 (1999) 153–163.
[67] Y.L. Muller, R. Reitstetter, A.J. Yool, Antisense knockdown of calcium-dependent
K+ channels in developing cerebellar Purkinje neurons, Brain Res. Dev. Brain
Res. 120 (2000) 135–140.
[68] S. Hamm, E. Latz, D. Hangel, T. Muller, P. Yu, D. Golenbock, T. Sparwasser, H.
Wagner, S. Bauer, Alternating 2′-O-ribose methylation is a universal approach for
generating non-stimulatory siRNA by acting as TLR7 antagonist, Immunobiology
215 (2010) 559–569.
[69] L. Ma, D.D. Wang, T.Y. Zhang, H. Yu, Y. Wang, S.H. Huang, F.S. Lee, Z.Y. Chen,
Region-speciﬁc involvement of BDNF secretion and synthesis in conditioned
taste aversion memory formation, J. Neurosci. 31 (2011) 2079–2090.
[70] M. Robbins, A. Judge, L. Liang, K. McClintock, E. Yaworski, I. MacLachlan, 2′-O-
methyl-modiﬁed RNAs act as TLR7 antagonists, Mol. Ther. 15 (2007) 1663–1669.
[71] Y. Hua, K. Sahashi, G. Hung, F. Rigo, M.A. Passini, C.F. Bennett, A.R. Krainer,
Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III
SMA mouse model, Genes Dev. 24 (2010) 1634–1644.
[72] M. Frieden, H.F. Hansen, T. Koch, Nuclease stability of LNA oligonucleotides and
LNA–DNA chimeras, Nucleosides Nucleotides Nucleic Acids 22 (2003) 1041–1043.
[73] D.A. Braasch, Y. Liu, D.R. Corey, Antisense inhibition of gene expression in cells
by oligonucleotides incorporating locked nucleic acids: effect of mRNA target
sequence and chimera design, Nucleic Acids Res. 30 (2002) 5160–5167.
[74] A.N. Elayadi, D.A. Braasch, D.R. Corey, Implications of high-afﬁnity hybridization by
locked nucleic acid oligomers for inhibition of human telomerase, Biochemistry 41
(2002) 9973–9981.
[75] J. Kurreck, E. Wyszko, C. Gillen, V.A. Erdmann, Design of antisense oligonucleotides
stabilized by locked nucleic acids, Nucleic Acids Res. 30 (2002) 1911–1918.
[76] M.D. Sorensen, L. Kvaerno, T. Bryld, A.E. Hakansson, B. Verbeure, G. Gaubert, P.
Herdewijn, J. Wengel, Alpha-L-ribo-conﬁgured locked nucleic acid (alpha-
L-LNA): synthesis and properties, J. Am. Chem. Soc. 124 (2002) 2164–2176.
[77] E.E. Swayze, A.M. Siwkowski, E.V. Wancewicz, M.T. Migawa, T.K. Wyrzykiewicz, G.
Hung, B.P. Monia, C.F. Bennett, Antisense oligonucleotides containing locked
nucleic acid improve potency but cause signiﬁcant hepatotoxicity in animals,
Nucleic Acids Res. 35 (2007) 687–700.
[78] C. Wahlestedt, P. Salmi, L. Good, J. Kela, T. Johnsson, T. Hokfelt, C. Broberger, F.
Porreca, J. Lai, K. Ren, et al., Potent and nontoxic antisense oligonucleotides
containing locked nucleic acids, Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 5633–5638.
[79] H. Gruegelsiepe, O. Brandt, R.K. Hartmann, Antisense inhibition of RNase P:
mechanistic aspects and application to live bacteria, J. Biol. Chem. 281 (2006)
30613–30620.
[80] R. Noir, M. Kotera, B. Pons, J.S. Remy, J.P. Behr, Oligonucleotide–oligospermine
conjugates (zip nucleic acids): a convenient means of ﬁnely tuning hybridization
temperatures, J. Am. Chem. Soc. 130 (2008) 13500–13505.
[81] K.T. Gagnon, J.K. Watts, H.M. Pendergraff, C. Montaillier, D. Thai, P. Potier, D.R. Corey,
Antisense and antigene inhibition of gene expression by cell-permeable oligonucleo-
tide–oligospermine conjugates, J. Am. Chem. Soc. 133 (2011) 8404–8407.
101M.M. Evers et al. / Advanced Drug Delivery Reviews 87 (2015) 90–103[82] D. Renneberg, C.J. Leumann,Watson–Crick base-pairing properties of tricyclo-DNA,
J. Am. Chem. Soc. 124 (2002) 5993–6002.
[83] D. Renneberg, E. Bouliong, U. Reber, D. Schumperli, C.J. Leumann, Antisense
properties of tricyclo-DNA, Nucleic Acids Res. 30 (2002) 2751–2757.
[84] A. Goyenvalle, G. Grifﬁth, A. Babbs, S.E. Andaloussi, K. Ezzat, A. Avril, B. Dugovic, R.
Chaussenot, A. Ferry, T. Voit, et al., Functional correction in mouse models of mus-
cular dystrophy using exon-skipping tricyclo-DNA oligomers, Nat. Med. 21 (2015)
270–275.
[85] A.M. Kawasaki, M.D. Casper, S.M. Freier, E.A. Lesnik, M.C. Zounes, L.L. Cummins, C.
Gonzalez, P.D. Cook, Uniformly modiﬁed 2′-deoxy-2′-ﬂuoro phosphorothioate
oligonucleotides as nuclease-resistant antisense compounds with high afﬁnity
and speciﬁcity for RNA targets, J. Med. Chem. 36 (1993) 831–841.
[86] P.P. Seth, A. Siwkowski, C.R. Allerson,G. Vasquez, S. Lee, T.P. Prakash, G. Kinberger,M.T.
Migawa, H. Gaus, B. Bhat, et al., Design, synthesis and evaluation of constrained
methoxyethyl (cMOE) and constrained ethyl (cEt) nucleoside analogs, Nucleic Acids
Symp. Ser. (Oxf.) (2008) 553–554.
[87] A.L. Southwell, N.H. Skotte, H.B. Kordasiewicz, M.E. Ostergaard, A.T. Watt, J.B.
Carroll, C.N. Doty, E.B. Villanueva, E. Petoukhov, K. Vaid, et al., In vivo evaluation
of candidate allele-speciﬁc mutant huntingtin gene silencing antisense oligonucle-
otides, Mol. Ther. 22 (2014) 2093–2106.
[88] P.E. Nielsen, M. Egholm, R.H. Berg, O. Buchardt, Sequence-selective recognition of
DNA by strand displacement with a thymine-substituted polyamide, Science 254
(1991) 1497–1500.
[89] M. Egholm,O. Buchardt, L. Christensen, C. Behrens, S.M. Freier, D.A.Driver, R.H. Berg,
S.K. Kim, B. Norden, P.E. Nielsen, PNA hybridizes to complementary oligonucleo-
tides obeying the Watson–Crick hydrogen-bonding rules, Nature 365 (1993)
566–568.
[90] V.V. Demidov, V.N. Potaman, M.D. Frank-Kamenetskii, M. Egholm, O. Buchard, S.H.
Sonnichsen, P.E. Nielsen, Stability of peptide nucleic acids in human serum and
cellular extracts, Biochem. Pharmacol. 48 (1994) 1310–1313.
[91] F.P. Schwarz, S. Robinson, J.M. Butler, Thermodynamic comparison of PNA/DNA
and DNA/DNA hybridization reactions at ambient temperature, Nucleic Acids
Res. 27 (1999) 4792–4800.
[92] P. Wittung, J. Kajanus, K. Edwards, G. Haaima, P.E. Nielsen, B. Norden, B.G.
Malmstrom, Phospholipid membrane permeability of peptide nucleic acid, FEBS
Lett. 375 (1995) 27–29.
[93] B. Hyrup, P.E. Nielsen, Peptide nucleic acids (PNA): synthesis, properties and
potential applications, Bioorg. Med. Chem. 4 (1996) 5–23.
[94] G. Aldrian-Herrada, M.G. Desarmenien, H. Orcel, L. Boissin-Agasse, J. Mery, J.
Brugidou, A. Rabie, A peptide nucleic acid (PNA) is more rapidly internalized in
cultured neurons when coupled to a retro-inverso delivery peptide. The antisense
activity depresses the target mRNA and protein in magnocellular oxytocin
neurons, Nucleic Acids Res. 26 (1998) 4910–4916.
[95] Y. Turner, G. Wallukat, P. Saalik, B. Wiesner, S. Pritz, J. Oehlke, Cellular uptake and
biological activity of peptide nucleic acids conjugated with peptides with and
without cell-penetrating ability, J. Pept. Sci. 16 (2010) 71–80.
[96] B.M. Tyler, D.J. McCormick, C.V. Hoshall, C.L. Douglas, K. Jansen, B.W. Lacy, B.
Cusack, E. Richelson, Speciﬁc gene blockade shows that peptide nucleic acids
readily enter neuronal cells in vivo, FEBS Lett. 421 (1998) 280–284.
[97] B.M. McMahon, D. Mays, J. Lipsky, J.A. Stewart, A. Fauq, E. Richelson, Pharmacoki-
netics and tissue distribution of a peptide nucleic acid after intravenous adminis-
tration, Antisense Nucleic Acid Drug Dev. 12 (2002) 65–70.
[98] J. Summerton, D.Weller, Morpholino antisense oligomers: design, preparation, and
properties, Antisense Nucleic Acid Drug Dev. 7 (1997) 187–195.
[99] R.M. Hudziak, E. Barofsky, D.F. Barofsky, D.L. Weller, S.B. Huang, D.D. Weller, Resis-
tance of morpholino phosphorodiamidate oligomers to enzymatic degradation,
Antisense Nucleic Acid Drug Dev. 6 (1996) 267–272.
[100] G.R. Devi, T.M. Beer, C.L. Corless, V. Arora, D.L. Weller, P.L. Iversen, In vivo bioavail-
ability and pharmacokinetics of a c-MYC antisense phosphorodiamidate
morpholino oligomer, AVI-4126, in solid tumors, Clin. Cancer Res. 11 (2005)
3930–3938.
[101] B. Wu, H.M. Moulton, P.L. Iversen, J. Jiang, J. Li, J. Li, C.F. Spurney, A. Sali, A.D.
Guerron, K. Nagaraju, et al., Effective rescue of dystrophin improves cardiac
function in dystrophin-deﬁcient mice by a modiﬁed morpholino oligomer, Proc.
Natl. Acad. Sci. U. S. A. 105 (2008) 14814–14819.
[102] P.N. Porensky, C. Mitrpant, V.L. McGovern, A.K. Bevan, K.D. Foust, B.K. Kaspar, S.D.
Wilton, A.H. Burghes, A single administration of morpholino antisense oligomer
rescues spinal muscular atrophy in mouse, Hum. Mol. Genet. 21 (2012) 1625–1638.
[103] M. Nizzardo, C. Simone, S. Salani, M.D. Ruepp, F. Rizzo, M. Ruggieri, C. Zanetta, S.
Brajkovic, H.M. Moulton, O. Muehlemann, et al., Effect of combined systemic and
local morpholino treatment on the spinal muscular atrophy Delta7 mouse model
phenotype, Clin. Ther. 36 (2014) 340–356.
[104] P.A. Morcos, Y. Li, S. Jiang, Vivo-Morpholinos: a non-peptide transporter delivers
morpholinos into a wide array of mouse tissues, Biotechniques 45 (2008)
613–614 (616, 618).
[105] D.P. Ferguson, L.J. Dangott, J.T. Lightfoot, Lessons learned from vivo-morpholinos:
how to avoid vivo-morpholino toxicity, Biotechniques 56 (2014) 251–256.
[106] H. Zhou, N. Janghra, C.Mitrpant, R.L. Dickinson, K. Anthony, L. Price, I.C. Eperon, S.D.
Wilton, J. Morgan, F. Muntoni, A novel morpholino oligomer targeting ISS-N1
improves rescue of severe spinal muscular atrophy transgenic mice, Hum. Gene
Ther. 24 (2013) 331–342.
[107] D.P. Ferguson, E.E. Schmitt, J.T. Lightfoot, Vivo-morpholinos induced transient
knockdown of physical activity related proteins, PLoS ONE 8 (2013) e61472.
[108] K.J. Reissner, G.C. Sartor, E.M. Vazey, T.E. Dunn, G. Aston-Jones, P.W. Kalivas, Use of
vivo-morpholinos for control of protein expression in the adult rat brain, J.
Neurosci. Methods 203 (2012) 354–360.[109] M. Teplova, S.T. Wallace, V. Tereshko, G. Minasov, A.M. Symons, P.D. Cook, M.
Manoharan, M. Egli, Structural origins of the exonuclease resistance of a zwitter-
ionic RNA, Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 14240–14245.
[110] N.B. Chauhan, G.J. Siegel, Antisense inhibition at the beta-secretase-site of
beta-amyloid precursor protein reduces cerebral amyloid and acetyl cholinesterase
activity in Tg2576, Neuroscience 146 (2007) 143–151.
[111] M.M. Evers, B.A. Pepers, J.C. van Deutekom, S.A. Mulders, J.T. den Dunnen, A.
Aartsma-Rus, G.J. van Ommen, W.M. van Roon-Mom, Targeting several CAG ex-
pansion diseases by a single antisense oligonucleotide, PLoS ONE 6 (2011) e24308.
[112] J. Hu, M. Matsui, K.T. Gagnon, J.C. Schwartz, S. Gabillet, K. Arar, J. Wu, I.
Bezprozvanny, D.R. Corey, Allele-speciﬁc silencing of mutant huntingtin and
ataxin-3 genes by targeting expanded CAG repeats in mRNAs, Nat. Biotechnol.
27 (2009) 478–484.
[113] X. Sun, L.O. Marque, Z. Cordner, J.L. Pruitt, M. Bhat, P.P. Li, G. Kannan, E.E.
Ladenheim, T.H. Moran, R.L. Margolis, et al., Phosphorodiamidate morpholino
oligomers suppress mutant huntingtin expression and attenuate neurotoxicity,
Hum. Mol. Genet. 23 (2014) 6302–6317.
[114] V.M. Miller, H. Xia, G.L. Marrs, C.M. Gouvion, G. Lee, B.L. Davidson, H.L. Paulson,
Allele-speciﬁc silencing of dominant disease genes, Proc. Natl. Acad. Sci. U. S. A.
100 (2003) 7195–7200.
[115] R. Kole, A.R. Krainer, S. Altman, RNA therapeutics: beyond RNA interference and
antisense oligonucleotides, Nat. Rev. Drug Discov. 11 (2012) 125–140.
[116] G.J. van Ommen, A. Aartsma-Rus, Advances in therapeutic RNA-targeting, N.
Biotechnol. 30 (2013) 299–301.
[117] E.S. Lander, L.M. Linton, B. Birren, C. Nusbaum, M.C. Zody, J. Baldwin, K. Devon, K.
Dewar, M. Doyle, W. FitzHugh, et al., Initial sequencing and analysis of the
human genome, Nature 409 (2001) 860–921.
[118] G. Yeo, D. Holste, G. Kreiman, C.B. Burge, Variation in alternative splicing across
human tissues, Genome Biol. 5 (2004) R74.
[119] I. Zalachoras, G. Grootaers, L.T. van Weert, Y. Aubert, S.R. de Kreij, N.A. Datson,
W.M. van Roon-Mom, A. Aartsma-Rus, O.C. Meijer, Antisense-mediated isoform
switching of steroid receptor coactivator-1 in the central nucleus of the amygdala
of the mouse brain, BMC Neurosci. 14 (2013) 5.
[120] N.K. Singh, N.N. Singh, E.J. Androphy, R.N. Singh, Splicing of a critical exon of
human survival motor neuron is regulated by a unique silencer element located
in the last intron, Mol. Cell. Biol. 26 (2006) 1333–1346.
[121] M.M. Evers, H.D. Tran, I. Zalachoras, B.A. Pepers, O.C. Meijer, J.T. den Dunnen, G.J.
van Ommen, A. Aartsma-Rus, W.M. van Roon-Mom, Ataxin-3 protein modiﬁcation
as a treatment strategy for spinocerebellar ataxia type 3: removal of the CAG
containing exon, Neurobiol. Dis. 58 (2013) 49–56.
[122] L. Du, J.M. Pollard, R.A. Gatti, Correction of prototypic ATM splicing mutations and
aberrant ATM function with antisense morpholino oligonucleotides, Proc. Natl.
Acad. Sci. U. S. A. 104 (2007) 6007–6012.
[123] J.R. Mendell, L.R. Rodino-Klapac, Z. Sahenk, K. Roush, L. Bird, L.P. Lowes, L. Alfano,
A.M. Gomez, S. Lewis, J. Kota, et al., Eteplirsen for the treatment of Duchenne
muscular dystrophy, Ann. Neurol. 74 (2013) 637–647.
[124] T. Voit, H. Topaloglu, V. Straub, F. Muntoni, N. Deconinck, G. Campion, S.J. de Kimpe,
M. Eagle, M. Guglieri, S. Hood, et al., Safety and efﬁcacy of drisapersen for the treat-
ment of Duchennemuscular dystrophy (DEMAND II): an exploratory, randomised,
placebo-controlled phase 2 study, Lancet Neurol. 13 (2014) 987–996.
[125] T.M. Wheeler, A.J. Leger, S.K. Pandey, A.R. MacLeod, M. Nakamori, S.H. Cheng, B.M.
Wentworth, C.F. Bennett, C.A. Thornton, Targeting nuclear RNA for in vivo
correction of myotonic dystrophy, Nature 488 (2012) 111–115.
[126] F. Shi, N.V. Gounko, X. Wang, E. Ronken, D. Hoekstra, In situ entry of oligonucleotides
into brain cells can occur through a nucleic acid channel, Oligonucleotides 17 (2007)
122–133.
[127] R.S. Geary, E. Wancewicz, J. Matson, M. Pearce, A. Siwkowski, E. Swayze, F. Bennett,
Effect of dose and plasma concentration on liver uptake and pharmacologic activity
of a 2′-methoxyethyl modiﬁed chimeric antisense oligonucleotide targeting PTEN,
Biochem. Pharmacol. 78 (2009) 284–291.
[128] R.L. Juliano, X. Ming, O. Nakagawa, Cellular uptake and intracellular trafﬁcking of
antisense and siRNA oligonucleotides, Bioconjug. Chem. 23 (2012) 147–157.
[129] E. Koller, T.M. Vincent, A. Chappell, S. De, M. Manoharan, C.F. Bennett, Mechanisms
of single-stranded phosphorothioate modiﬁed antisense oligonucleotide accumu-
lation in hepatocytes, Nucleic Acids Res. 39 (2011) 4795–4807.
[130] H. Heemskerk, C. de Winter, P. van Kuik, N. Heuvelmans, P. Sabatelli, P. Rimessi, P.
Braghetta, G.J. van Ommen, S. de Kimpe, A. Ferlini, et al., Preclinical PK and PD
studies on 2′-O-methyl-phosphorothioate RNA antisense oligonucleotides in the
mdx mouse model, Mol. Ther. 18 (2010) 1210–1217.
[131] I.E. Verhaart, van Vliet-van den Dool, J.A. Sipkens, S.J. de Kimpe, I.G. Kolfschoten, J.C.
van Deutekom, L. Liefaard, J.E. Ridings, S.R. Hood, A. Aartsma-Rus, The dynamics of
compound, transcript, and protein effects after treatment with 2OMePS antisense
oligonucleotides in mdx mice, Mol. Ther. Nucleic Acids 3 (2014) e148.
[132] F. Rigo, S.J. Chun, D.A. Norris, G. Hung, S. Lee, J. Matson, R.A. Fey, H. Gaus, Y. Hua, J.S.
Grundy, et al., Pharmacology of a central nervous system delivered 2′-O-
methoxyethyl-modiﬁed survival of motor neuron splicing oligonucleotide in
mice and nonhuman primates, J. Pharmacol. Exp. Ther. 350 (2014) 46–55.
[133] R.A. Smith, T.M. Miller, K. Yamanaka, B.P. Monia, T.P. Condon, G. Hung, C.S.
Lobsiger, C.M.Ward, M. McAlonis-Downes, H. Wei, et al., Antisense oligonucle-
otide therapy for neurodegenerative disease, J. Clin. Invest. 116 (2006)
2290–2296.
[134] R. Sud, E.T. Geller, G.D. Schellenberg, Antisense-mediated exon skipping decreases
tau protein expression: a potential therapy for tauopathies, Mol. Ther. Nucleic
Acids 3 (2014) e180.
[135] A. Aartsma-Rus, L. van Vliet, M. Hirschi, A.A. Janson, H. Heemskerk, C.L. de Winter,
S. de Kimpe, J.C. van Deutekom, P.A. 't Hoen, G.J. van Ommen, Guidelines for
102 M.M. Evers et al. / Advanced Drug Delivery Reviews 87 (2015) 90–103antisense oligonucleotide design and insight into splice-modulating mechanisms,
Mol. Ther. 17 (2009) 548–553.
[136] B. Van Broeck, C. Van Broeckhoven, S. Kumar-Singh, Current insights into
molecular mechanisms of Alzheimer disease and their implications for therapeutic
approaches, Neurodegener. Dis. 4 (2007) 349–365.
[137] L.M. Ittner, J. Gotz, Amyloid-beta and tau — a toxic pas de deux in Alzheimer's
disease, Nat. Rev. Neurosci. 12 (2011) 65–72.
[138] A. Al-Chalabi, P.N. Leigh, Recent advances in amyotrophic lateral sclerosis, Curr.
Opin. Neurol. 13 (2000) 397–405.
[139] A.E. Renton, A. Chio, B.J. Traynor, State of play in amyotrophic lateral sclerosis
genetics, Nat. Neurosci. 17 (2014) 17–23.
[140] M. DeJesus-Hernandez, I.R. Mackenzie, B.F. Boeve, A.L. Boxer, M. Baker, N.J.
Rutherford, A.M. Nicholson, N.A. Finch, H. Flynn, J. Adamson, et al., Expanded
GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes
chromosome 9p-linked FTD and ALS, Neuron 72 (2011) 245–256.
[141] T. Lashley, J. Hardy, A.M. Isaacs, RANTing about C9orf72, Neuron 77 (2013)
597–598.
[142] C.J. Donnelly, P.W. Zhang, J.T. Pham, A.R. Haeusler, N.A. Mistry, S. Vidensky, E.L.
Daley, E.M. Poth, B. Hoover, D.M. Fines, et al., RNA toxicity from the ALS/FTD
C9ORF72 expansion is mitigated by antisense intervention, Neuron 80 (2013)
415–428.
[143] C. Lagier-Tourenne, M. Baughn, F. Rigo, S. Sun, P. Liu, H.R. Li, J. Jiang, A.T. Watt, S.
Chun, M. Katz, et al., Targeted degradation of sense and antisense C9orf72 RNA
foci as therapy for ALS and frontotemporal degeneration, Proc. Natl. Acad. Sci. U.
S. A. 110 (2013) E4530–E4539.
[144] G. Riboldi, C. Zanetta, M. Ranieri, M. Nizzardo, C. Simone, F. Magri, N. Bresolin, G.P.
Comi, S. Corti, Antisense oligonucleotide therapy for the treatment of C9ORF72
ALS/FTD diseases, Mol. Neurobiol. 50 (2014) 721–732.
[145] D.W. Sah, N. Aronin, Oligonucleotide therapeutic approaches for Huntington
disease, J. Clin. Invest. 121 (2011) 500–507.
[146] K.H. Fischbeck, Polyglutamine expansion neurodegenerative disease, Brain Res.
Bull. 56 (2001) 161–163.
[147] S.W. Davies, M. Turmaine, B.A. Cozens, M. DiFiglia, A.H. Sharp, C.A. Ross, E.
Scherzinger, E.E. Wanker, L. Mangiarini, G.P. Bates, Formation of neuronal
intranuclear inclusions underlies the neurological dysfunction in mice transgenic
for the HD mutation, Cell 90 (1997) 537–548.
[148] K. Seidel, S. Siswanto, E.R. Brunt, W. den Dunnen, H.W. Korf, U. Rub, Brain
pathology of spinocerebellar ataxias, Acta Neuropathol. 124 (2012) 1–21.
[149] B. Cannella, C.S. Raine, The adhesion molecule and cytokine proﬁle of multiple
sclerosis lesions, Ann. Neurol. 37 (1995) 424–435.
[150] D.M. Rose, R. Alon, M.H. Ginsberg, Integrin modulation and signaling in leukocyte
adhesion and migration, Immunol. Rev. 218 (2007) 126–134.
[151] R.R. Lobb, M.E. Hemler, The pathophysiologic role of alpha 4 integrins in vivo, J.
Clin. Invest. 94 (1994) 1722–1728.
[152] K.J. Myers, D.R. Witchell, M.J. Graham, S. Koo, M. Butler, T.P. Condon, Antisense
oligonucleotide blockade of alpha 4 integrin prevents and reverses clinical symp-
toms in murine experimental autoimmune encephalomyelitis, J. Neuroimmunol.
160 (2005) 12–24.
[153] K. Nazor Friberg, G. Hung, E. Wancewicz, K. Giles, C. Black, S. Freier, F. Bennett, S.J.
Dearmond, Y. Freyman, P. Lessard, et al., Intracerebral infusion of antisense
oligonucleotides into prion-infected mice, Mol. Ther. Nucleic Acids 1 (2012) e9.
[154] G. Puoti, A. Bizzi, G. Forloni, J.G. Safar, F. Tagliavini, P. Gambetti, Sporadic human
prion diseases: molecular insights and diagnosis, Lancet Neurol. 11 (2012)
618–628.
[155] M.V. Karpuj, K. Giles, S. Gelibter-Niv, M.R. Scott, V.R. Lingappa, F.C. Szoka, D. Peretz,
W. Denetclaw, S.B. Prusiner, Phosphorothioate oligonucleotides reduce PrP levels
and prion infectivity in cultured cells, Mol. Med. 13 (2007) 190–198.
[156] D.A. Kocisko, A. Vaillant, K.S. Lee, K.M. Arnold, N. Bertholet, R.E. Race, E.A. Olsen,
J.M. Juteau, B. Caughey, Potent antiscrapie activities of degenerate phosphorothio-
ate oligonucleotides, Antimicrob. Agents Chemother. 50 (2006) 1034–1044.
[157] N.H. Skotte, A.L. Southwell, M.E. Ostergaard, J.B. Carroll, S.C. Warby, C.N. Doty, E.
Petoukhov, K. Vaid, H. Kordasiewicz, A.T. Watt, et al., Allele-speciﬁc suppression
of mutant huntingtin using antisense oligonucleotides: providing a therapeutic
option for all Huntington disease patients, PLoS ONE 9 (2014) e107434.
[158] J.B. Carroll, S.C.Warby, A.L. Southwell, C.N. Doty, S. Greenlee, N. Skotte, G. Hung, C.F.
Bennett, S.M. Freier, M.R. Hayden, Potent and selective antisense oligonucleotides
targeting single-nucleotide polymorphisms in the Huntington disease gene/
allele-speciﬁc silencing of mutant huntingtin, Mol. Ther. 19 (2011) 2178–2185.
[159] M.E. Ostergaard, A.L. Southwell, H. Kordasiewicz, A.T. Watt, N.H. Skotte, C.N. Doty,
K. Vaid, E.B. Villanueva, E.E. Swayze, C.F. Bennett, et al., Rational design of antisense
oligonucleotides targeting single nucleotide polymorphisms for potent and allele
selective suppression of mutant Huntingtin in the CNS, Nucleic Acids Res. 41
(2013) 9634–9650.
[160] D. Selkoe, R. Kopan, Notch and Presenilin: regulated intramembrane proteolysis
links development and degeneration, Annu. Rev. Neurosci. 26 (2003) 565–597.
[161] C.L. Lorson, H. Rindt, M. Shababi, Spinal muscular atrophy: mechanisms and
therapeutic strategies, Hum. Mol. Genet. 19 (2010) R111–R118.
[162] M.A. Passini, J. Bu, A.M. Richards, C. Kinnecom, S.P. Sardi, L.M. Stanek, Y. Hua, F.
Rigo, J. Matson, G. Hung, et al., Antisense oligonucleotides delivered to the
mouse CNS ameliorate symptoms of severe spinal muscular atrophy, Sci. Transl.
Med. 3 (2011) 72ra18.
[163] S.R. Lim, K.J. Hertel, Modulation of survival motor neuron pre-mRNA splicing
by inhibition of alternative 3′ splice site pairing, J. Biol. Chem. 276 (2001)
45476–45483.
[164] J.H. Williams, R.C. Schray, C.A. Patterson, S.O. Ayitey, M.K. Tallent, G.J. Lutz,
Oligonucleotide-mediated survival of motor neuron protein expression in CNSimproves phenotype in a mouse model of spinal muscular atrophy, J. Neurosci.
29 (2009) 7633–7638.
[165] F. Rigo, Y. Hua, A.R. Krainer, C.F. Bennett, Antisense-based therapy for the
treatment of spinal muscular atrophy, J. Cell Biol. 199 (2012) 21–25.
[166] Isis Pharmaceuticals, An Open-label Safety, Tolerability and Dose-range Finding
Study of Multiple Doses of ISIS SMNRx in Patient With Spinal Muscular Atrophy
(SMNRx — CS2), ClinicalTrials. gov NCT01703988, 2012.
[167] N. Sandoval, M. Platzer, A. Rosenthal, T. Dork, R. Bendix, B. Skawran,M. Stuhrmann,
R.D. Wegner, K. Sperling, S. Banin, et al., Characterization of ATM genemutations in
66 ataxia telangiectasia families, Hum. Mol. Genet. 8 (1999) 69–79.
[168] E.C. Madsen, P.A. Morcos, B.A. Mendelsohn, J.D. Gitlin, In vivo correction of a
Menkes disease model using antisense oligonucleotides, Proc. Natl. Acad. Sci. U.
S. A. 105 (2008) 3909–3914.
[169] C. Vulpe, B. Levinson, S. Whitney, S. Packman, J. Gitschier, Isolation of a candidate
gene for Menkes disease and evidence that it encodes a copper-transporting
ATPase, Nat. Genet. 3 (1993) 7–13.
[170] Z. Tumer, L.B. Moller, Menkes disease, Eur. J. Hum. Genet. 18 (2010) 511–518.
[171] C.P. Donahue, C. Muratore, J.Y. Wu, K.S. Kosik, M.S. Wolfe, Stabilization of the tau
exon10 stem loop alters pre-mRNA splicing, J. Biol. Chem. 281 (2006) 23302–23306.
[172] E. Peacey, L. Rodriguez, Y. Liu, M.S. Wolfe, Targeting a pre-mRNA structure with bi-
partite antisense molecules modulates tau alternative splicing, Nucleic Acids Res.
40 (2012) 9836–9849.
[173] N. Gustke, B. Trinczek, J. Biernat, E.M. Mandelkow, E. Mandelkow, Domains of tau
protein and interactions with microtubules, Biochemistry 33 (1994) 9511–9522.
[174] M. Hutton, C.L. Lendon, P. Rizzu, M. Baker, S. Froelich, H. Houlden, S. Pickering-Brown,
S. Chakraverty, A. Isaacs, A. Grover, et al., Association of missense and 5′-splice-site
mutations in tau with the inherited dementia FTDP-17, Nature 393 (1998) 702–705.
[175] M.M. Evers, H.D. Tran, I. Zalachoras, O.C. Meijer, J.T. den Dunnen, G.J. van Ommen,
A. Aartsma-Rus, W.M. van Roon-Mom, Preventing formation of toxic N-terminal
huntingtin fragments through antisense oligonucleotide-mediated protein
modiﬁcation, Nucleic Acid Ther. 24 (2014) 4–12.
[176] J.K. Cooper, G. Schilling, M.F. Peters, W.J. Herring, A.H. Sharp, Z. Kaminsky, J.
Masone, F.A. Khan, M. Delanoy, D.R. Borchelt, et al., Truncated N-terminal
fragments of huntingtin with expanded glutamine repeats form nuclear and
cytoplasmic aggregates in cell culture, Hum. Mol. Genet. 7 (1998) 783–790.
[177] R.K. Graham, Y. Deng, E.J. Slow, B. Haigh, N. Bissada, G. Lu, J. Pearson, J. Shehadeh, L.
Bertram, Z. Murphy, et al., Cleavage at the caspase-6 site is required for neuronal
dysfunction and degeneration due to mutant huntingtin, Cell 125 (2006)
1179–1191.
[178] L.M. Mende-Mueller, T. Toneff, S.R. Hwang, M.F. Chesselet, V.Y. Hook, Tissue-
speciﬁc proteolysis of Huntingtin (htt) in human brain: evidence of enhanced
levels of N- and C-terminal htt fragments in Huntington's disease striatum,
J. Neurosci. 21 (2001) 1830–1837.
[179] M. Rydh-Rinder, O.G. Berge, T. Hokfelt, Antinociceptive effects after intrathecal
administration of phosphodiester-, 2′-O-allyl-, and C-5-propyne-modiﬁed
antisense oligodeoxynucleotides targeting the NMDAR1 subunit in mouse, Brain
Res. Mol. Brain Res. 86 (2001) 23–33.
[180] W.J. Wojcik, P. Swoveland, X. Zhang, P. Vanguri, Chronic intrathecal infusion of
phosphorothioate or phosphodiester antisense oligonucleotides against cytokine
responsive gene-2/IP-10 in experimental allergic encephalomyelitis of lewis rat,
J. Pharmacol. Exp. Ther. 278 (1996) 404–410.
[181] Y. Yaida, T.S. Nowak Jr., Distribution of phosphodiester and phosphorothioate oli-
gonucleotides in rat brain after intraventricular and intrahippocampal administra-
tion determined by in situ hybridization, Regul. Pept. 59 (1995) 193–199.
[182] W.C. Broaddus, S.S. Prabhu, G.T. Gillies, J. Neal, W.S. Conrad, Z.J. Chen, H. Fillmore,
H.F. Young, Distribution and stability of antisense phosphorothioate oligonucleo-
tides in rodent brain following direct intraparenchymal controlled-rate infusion,
Neurosurg. Focus. 3 (1997) (Article 4).
[183] A. Carpentier, F. Laigle-Donadey, S. Zohar, L. Capelle, A. Behin, A. Tibi, N. Martin-
Duverneuil, M. Sanson, L. Lacomblez, S. Taillibert, et al., Phase 1 trial of a CpG
oligodeoxynucleotide for patients with recurrent glioblastoma, Neuro Oncol. 8
(2006) 60–66.
[184] R. Schlingensiepen, M. Goldbrunner, M.N. Szyrach, G. Stauder, P. Jachimczak, U.
Bogdahn, F. Schulmeyer, P. Hau, K.H. Schlingensiepen, Intracerebral and intrathecal
infusion of the TGF-beta 2-speciﬁc antisense phosphorothioate oligonucleotide
AP 12009 in rabbits and primates: toxicology and safety, Oligonucleotides 15
(2005) 94–104.
[185] T.D. Charlier, G.F. Ball, J. Balthazart, Inhibition of steroid receptor coactivator-1
blocks estrogen and androgen action on male sex behavior and associated brain
plasticity, J. Neurosci. 25 (2005) 906–913.
[186] E.Y. Osman, P.F. Yen, C.L. Lorson, Bifunctional RNAs targeting the intronic splicing
silencer N1 increase SMN levels and reduce disease severity in an animal model
of spinal muscular atrophy, Mol. Ther. 20 (2012) 119–126.
[187] P.W. Pao, K.B. Wee, W.C. Yee, Z.A. Pramono, Dual masking of speciﬁc negative
splicing regulatory elements resulted in maximal exon 7 inclusion of SMN2
gene, Mol. Ther. 22 (2014) 854–861.
[188] E.D. Koval, C. Shaner, P. Zhang, X. du Maine, K. Fischer, J. Tay, B.N. Chau, G.F. Wu,
T.M. Miller, Method for widespread microRNA-155 inhibition prolongs survival
in ALS-model mice, Hum. Mol. Genet. 22 (2013) 4127–4135.
[189] E.Y. Osman, M.R. Miller, K.L. Robbins, A.M. Lombardi, A.K. Atkinson, A.J. Brehm, C.L.
Lorson, Morpholino antisense oligonucleotides targeting intronic repressor Ele-
ment1 improve phenotype in SMA mouse models, Hum. Mol. Genet. 23 (2014)
4832–4845.
[190] M. Boules, K. Williams, E. Gollatz, A. Fauq, E. Richelson, Down-regulation of amy-
loid precursor protein by peptide nucleic acid in vivo, J. Mol. Neurosci. 24 (2004)
123–128.
103M.M. Evers et al. / Advanced Drug Delivery Reviews 87 (2015) 90–103[191] B.J. Turner, I.K. Cheah, K.J. Macfarlane, E.C. Lopes, S. Petratos, S.J. Langford, S.S.
Cheema, Antisense peptide nucleic acid-mediated knockdown of the p75
neurotrophin receptor delays motor neuron disease in mutant SOD1 transgenic
mice, J. Neurochem. 87 (2003) 752–763.
[192] Isis Pharmaceuticals, Safety, Tolerability, and Activity Study of ISIS SOD1Rx to Treat
Familial Amyotrophic Lateral Sclerosis (ALS) Caused by SOD1 Gene Mutations
(SOD-1), ClinicalTrials. gov NCT01041222, 2009.
[193] Y. Hua, K. Sahashi, F. Rigo, G. Hung, G. Horev, C.F. Bennett, A.R. Krainer, Peripheral
SMN restoration is essential for long-term rescue of a severe spinal muscular atro-
phy mouse model, Nature 478 (2011) 123–126.
[194] G. Marc, R. Leah, E. Oﬁra, A. Oded, A. Zohar, R. Hanna, Presymptomatic treatment
with acetylcholinesterase antisense oligonucleotides prolongs survival in ALS
(G93A-SOD1) mice, Biomed. Res. Int. 2013 (2013) 845345.
[195] L. Winer, D. Srinivasan, S. Chun, D. Lacomis, M. Jaffa, A. Fagan, D.M. Holtzman, E.
Wancewicz, C.F. Bennett, R. Bowser, et al., SOD1 in cerebral spinal ﬂuid as a
pharmacodynamic marker for antisense oligonucleotide therapy, JAMA Neurol.
70 (2013) 201–207.[196] A. Rembach, B.J. Turner, S. Bruce, I.K. Cheah, R.L. Scott, E.C. Lopes, C.J. Zagami, P.M.
Beart, N.S. Cheung, S.J. Langford, et al., Antisense peptide nucleic acid targeting
GluR3 delays disease onset and progression in the SOD1 G93A mouse model of
familial ALS, J. Neurosci. Res. 77 (2004) 573–582.
[197] L.M. Stanek,W. Yang, S. Angus, P.S. Sardi, M.R. Hayden, G.H. Hung, C.F. Bennett, S.H.
Cheng, L.S. Shihabuddin, Antisense oligonucleotide-mediated correction of
transcriptional dysregulation is correlated with behavioral beneﬁts in the
YAC128 mouse model of Huntington's disease, J. Huntingtons Dis. 2 (2013)
217–228.
[198] S.A. Farr, J.L. Ripley, R. Sultana, Z. Zhang, M.L. Niehoff, T.L. Platt, M.P. Murphy, J.E.
Morley, V. Kumar, D.A. Butterﬁeld, Antisense oligonucleotide against GSK-3beta
in brain of SAMP8 mice improves learning and memory and decreases oxidative
stress: involvement of transcription factor Nrf2 and implications for Alzheimer
disease, Free Radic. Biol. Med. 67 (2014) 387–395.
